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AbstrAct
Cancer is a complex disease, characterized by alteration of different physiological 
molecular processes and cellular features. Keeping this in mind, the possibility of early 
identification and detection of specific tumor biomarkers by non-invasive approaches 
could improve early diagnosis and patient management. 
Different molecular imaging procedures provide powerful tools for detection 
and non-invasive characterization of oncological lesions. Clinical studies are mainly 
based on the use of computed tomography, nuclear-based imaging techniques and 
magnetic resonance imaging. Preclinical imaging in small animal models entails the 
use of dedicated instruments, and beyond the already cited imaging techniques, 
it includes also optical imaging studies. Optical imaging strategies are based on 
the use of luminescent or fluorescent reporter genes or injectable fluorescent or 
luminescent probes that provide the possibility to study tumor features even by means 
of fluorescence and luminescence imaging. Currently, most of these probes are used 
only in animal models, but the possibility of applying some of them also in the clinics 
is under evaluation. 
The importance of tumor imaging, the ease of use of optical imaging instruments, 
the commercial availability of a wide range of probes as well as the continuous 
description of newly developed probes, demonstrate the significance of these 
applications. The aim of this review is providing a complete description of the 
possible optical imaging procedures available for the non-invasive assessment of 
tumor features in oncological murine models. In particular, the characteristics of both 
commercially available and newly developed probes will be outlined and discussed.
INtrODUctION
Cancer is a heterogeneous disease and different 
causal factors and processes are involved in its growth 
and progression. The possibility of early detection and 
characterization of tumor is of the utmost importance, 
because it increases the chances of treatment and cure. 
Imaging techniques, permitting to obtain non-
invasive images from the body, may help in the 
identification and localization of tumor lesions and in 
the characterization of processes involved in tumor 
proliferation and invasion, concurring to the description of 
tumor features, for a correct staging and the identification 
of the most efficacious treatment procedure and schedule.
Specific molecules, capable of tracing a precise 
event or a well-defined marker, have been labeled with 
different kinds of contrast agents, such as radionuclides for 
nuclear based imaging, paramagnetic or electron opaque 
substances for radiological techniques, or bioluminescent 
or fluorescent molecules for optical imaging. The signal 
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generated by contrast agents are then detected with the 
dedicated imaging technique. 
In the clinics, nuclear-based and radiological 
techniques are the most used procedures to identify tumor 
presence, and to monitor growth, staging and response to 
therapy. Even if new injectable fluorescent probes have 
been proposed for clinical use, their application is still 
limited. In pre-clinical oncological studies, in addition to 
magnetic resonance imaging, ultrasound and nuclear based 
imaging, optical imaging procedures can be affordable, 
using non-ionizing radiation and allowing a high-
throughput analysis of small animal models expressing 
specific reporters (Luciferase or red and near-infrared 
fluorescent proteins) or injected with specific fluorescent 
(or chemiluminescent) probes. Moreover, optical imaging 
instrumentation have been proposed for a novel application 
based on the acquisition of Čerenkov [1] radiation emitted 
by charged particles, such as radionuclides/radiotracers.
Optical imaging procedures include, in fact, 
different imaging possibilities such as: fluorescence (FLI), 
bioluminescence (BLI) (Figure 1) and Čerenkov (CLI) 
imaging. In this review, first of all the different strategies 
will be described and discussed, then the possibility of 
visualizing different tumor cell processes and cellular 
features using specific optical probes will be highlighted 
(Figure 2). Finally, a further section will explain the 
possibility of using these strategies for newly discovered 
cellular targets.
Fluorescence imaging (FLI)
Fluorescent imaging [2-4] is based on the detection 
of photons (wavelength range: 442-800 nm) produced 
by the return to ground state of electrons excited by 
photostimulation. These photons can be revealed by a 
cooled CCD-camera by using specific filters to select 
excitation and emission band and to reduce noise 
background. 
Fluorescence can be obtained through the use of 
fluorophores or reporter genes. The first strategy, in the 
same way of nuclear based imaging, in which a probe 
is labeled with a radiotracer, entails use of a fluorescent 
Table 1: List of fluotochromes used to label molecules (in order of emission wavelength).
FLUOrOcHrOME λmax EXcItAtION (nm) λmax EMIssION (nm)
Bodipy-FL 480 513
5-Carboxyfluorescein 492 517
AF488 498 520
RhodamineG 525 555
QD580 350 580
QD590 350 590
NANQ 463 615
QD645 350 645
645 649 666
Pyro a 412/670 675
AF680 675 693
Cy5.5 675 695
DY-676 676 705
QD705 350 705
DY-680 677 705
Cy7 743 767
ITCC 740 770
DY-750 751 772
AF750 755 775
IRD800 775 792
QD800 350 800
ICG 785 801
X-SIGHT760 760 813
QD820 350 820
QD840 350 840
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molecule able to report the localization of the conjugated 
probe. The second strategy is based instead on the use of 
reporter genes (such as Red Fluorescent Proteins -RFP, 
or mCherry) able to provide information about a specific 
process or molecular event (by using a specific promoter 
or by direct linking with a key molecule). Even if the first 
strategy is influenced by the size of fluorophore, that could 
affect the targeting or the biodistribution of the probes, it 
is easier to use compared to the second, because it does not 
require cell engineering to insert the reporter gene into the 
genome (the reporter molecules could also be conjugated 
to the probe, but there would be a significant increase in 
size).
FLI has several advantages: first, it does not 
require the administration of a substrate that has to be 
enzymatically modified to emit photons. Second, it allows 
to exploit different fluorophores with different spectra of 
excitation and emission (Table 1), characterized by high 
quantum yield and high penetration in tissues, to acquire 
multiple signals monitoring different processes in the 
Figure 1: Schematic representation of Optical Imaging. The strategies for optical imaging are based on: A. administration of 
probes or b. use of engineered mice expressing a reporter gene. Panel c. shows Fluorescence (dark box on the left side) or Bioluminescence 
Acquisition (dark box on the right side). CCD camera=Charged-Coupled Device camera.
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same experimental animal. Third, the same fluorescent 
signal can be used for the in vivo monitoring of a 
specific molecular process and its ex vivo validation by 
fluorescence microscopy. Last but not least, the availability 
of several specific probes for different processes has 
eliminated the need of developing new reporter gene 
expressing models, speeding up the translation of pre-
clinical data into the clinics.
Among disadvantages, FLI requires the use of an 
excitation light, that could be attenuated by the tissues with 
a consequent lower excitation efficiency of deeply located 
fluorochromes, and it is characterized by a significant 
amount of auto-fluorescence which determines a high 
background level due to the presence of endogenously 
fluorescent molecules. For this reason, the quantification 
of FL signal can be often difficult. 
bioluminescence imaging (bLI)
Bioluminescence [2,5] or chemiluminescence [6] 
imaging are based on the detection of photons produced 
by a chemical reaction: A + B → C + light, where A 
and B could be an enzyme and its substrate and C is the 
product(s) of the reaction. In this case the cooled CCD-
camera does not need filters, revealing all the photons 
emitted by the sample.
BLI is mainly based on the use of reporter genes 
encoding enzymes, as a rule Luciferase, able to emit 
photons in the presence of specific substrates, such as 
D-Luciferin for Firefly Luciferase or coelenterazine for 
Renilla Luciferase, in the wavelength range of 485-613 
nm, or reporter probes labeled with these enzymes or 
conjugated with chemi-luminescent molecules, such as 
luminol. 
Among the major advantages of BLI, there is 
the independence from an excitation light (reducing 
the photon attenuation, scattering and diffusion when 
compared with FLI, since photons cross tissues only once), 
and the absence of background signal due to luminescence 
emitting endogenous molecules, determining a more 
accurate signal quantification, resulting to be dependent by 
the number of luciferase expressing cells or the enzymatic 
chemiluminescent reaction.
BLI disadvantages are the requirement of substrate 
administration, the low penetration of emitted photons, 
and sometimes the longer acquisition time compared to 
fluorescence imaging (ranging from 1 second to 5 minutes 
for BLI imaging and from 1 second to 60 seconds for FLI 
imaging). Moreover, despite the large use of Luciferase as 
reporter gene for in vitro and in vivo imaging procedures, 
the requirement of cell engineering and the large size of 
bioluminescent enzymes for probe conjugation makes this 
strategy less appealing for the easy and fast visualization 
of oncological processes and features, even if some 
examples are given in this review. 
Figure 2: Tumor processes. Schematic representation of different processes involved in tumor growth and progression, that can be 
visualized by using imaging techniques.
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Čerenkov luminescence imaging (cLI)
The Čerenkov Imaging is based on the detection 
of photons emitted by a charged particle that moves 
through a dielectric medium at a speed higher than the 
velocity of light in that medium [1]. In molecular imaging 
applications, this process can be generated by high speed 
Compton electrons produced by gamma radiation (derived 
by nuclear decay of isotopes already used for nuclear 
based imaging techniques such as 18F, 11C, 99mTc and 131I), 
and an ultra-sensitive CCD camera for BLI can be used to 
reveal this visible light.
Čerenkov radiation can be used for non-invasive 
monitoring by CCD camera imaging of a radionuclide 
labeled tracer localization, or, instead of directly analyze 
Čerenkov radiation itself, the emission can be used as 
an internal excitation source for other fluorophores. The 
latter strategy permits the detection of signals with higher 
penetration compared to the former one, but it is less used.
There are several potential applications in the 
clinics and advantages of this kind of Optical Imaging 
procedure. The possibility to quantify in real time α and 
beta decay allows measuring dosimetry for a specific 
target organ during radiotherapy. The same radiation 
could be used during surgery or during endoscopy to drive 
tumor resection, in small animal tomography, or for the 
monitoring of pH or O
2
 levels [7-8].
The short range of photon penetration in tissues 
restricts whole body CLI to small animal imaging; 
human use is limited to near surface emissions such as 
visualization of thyroid [9], that showed a good agreement 
with PET scan. 
Despite the recent importance acquired by this 
technique, examples of Čerenkov Imaging will not be 
provided in this review, which focuses on the use of non-
radioactive probes.
Molecular sensitivity
The molecular sensitivity of an imaging technique 
is defined, from CS Levin, as the “capability to detect, 
visualize and accurately quantify low concentration of 
molecular probe interacting with a molecular target on 
or within cells of a living subject” [10]. In other words, 
sensitivity is the lower signal that can be detected by a 
specific imaging modality.
Considering optical imaging, FLI is characterized by 
a typical molecular sensitivity value that is over an order 
of magnitude lower compared to BLI (10-9 ÷ 10-11 and 10-13 
÷ 10-16, respectively [11]). 
Molecular sensitivity has been described by Levin 
to be dependent “by a combination of the probe and 
biological/physiological properties of the subject that 
determine its specificity for the target and the performance 
capabilities of the imaging system that determine how well 
the resulting signal can be detected and measured” [10]. 
Considering the latter part, some physical parameters 
should be taken into account to precisely define molecular 
sensitivity. It strongly depends on quantum efficiency 
and geometry of light sensor, probability of photons 
conversion to electric charge, background dark current 
(mainly due to sensor temperature), and the setting of 
acquisition parameters (binning, pixel size, exposure 
time, position of field of view). Most of these parameters 
influence sensitivity both for FLI and BLI, e.g. excitation 
light used in FLI is also involved by influencing quantum 
efficiency of light sensors, and can vary greatly from one 
imaging system to another. 
In addition to the specificity of probe-target 
interaction, that will be explained in the following 
paragraphs, biological background signal is the other 
significant variable to consider if we analyze molecular 
sensitivity. Background signal in FLI acquisitions is 
particularly important since it can be due to both auto-
fluorescence of endogenous fluorescent molecules present 
in the cells and tissues and by the a-specific uptake of 
a fluorophore labeled probe and can significantly vary 
specific fluorescence acquisition. 
MOLEcULAr PrOcEssEs
Metabolism
Metabolism is defined as the sum of the physical 
and chemical processes in a cell able to produce, maintain 
and destroy materials, and by which energy is made 
available. All metabolic processes are finely regulated 
into the cells, and studies carried out on tumor samples 
and clinical trials have indicated a strong relationship 
between activation of oncogenes and modification in 
cell metabolism. Cell metabolism modification is, in 
fact, a common tumor feature involving glucose, amino 
acid and/or lipid metabolism deregulation and can be 
considered as a surrogate biomarker correlated with tumor 
grade, proliferation rate, aggressiveness, etc. Molecular 
imaging highlighted the importance to visualize tumor 
metabolism, because this information could influence 
patient management, by improving tumor staging, re-
staging, radiation treatment planning, and monitoring of 
tumor response to therapy [12-13].
Regarding glucose metabolism, glycolysis is 
inhibited, in normal mammalian cells, by the presence of 
oxygen, which allows mitochondria to oxidize pyruvate 
to CO
2
 and H
2
O (Pasteur Effect); however, in cancer cells 
glycolysis is increased, and glucose is converted into lactic 
acid in presence of oxygen (a process that is called aerobic 
glycolysis). As firstly reported by Otto Warburg at the 
beginning of the 20th century, this is a specific metabolic 
abnormality of cancer cells.
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Glucose was firstly labeled with 14C and following 
with 18F to study glucose metabolism by PET, and to date, 
18F-FDG is the most used radiotracer for PET imaging. In 
order to study glucose uptake by fluorescence imaging, 
a more cost-effective, convenient, and high-throughput 
alternative to FDG-PET in pre-clinical imaging, glucose 
was also labeled with fluorophores [14]. The fluorescent 
2-deoxy-D-glucose (2-DG, commercially available by 
PerkinElmer Life Sciences, Inc, Boston, MA, USA and 
by LI-COR Biotechnology - GmbH, Bad Homburg, 
Germany) has been generated by substitution of 
2-hydroxyl group with various fluorophores emitting in 
the near infra-red (NIR) window (Cy5.5, ICG, IRD, etc.). 
Different studies [15-18] have reported the possibility to 
use 2-DG conjugates to efficiently visualize tumor masses 
in oncological murine models, with high selectivity 
of localization and retention in the lesions, even if the 
conjugation of 2-DG with NIR-fluorophores determines 
a significant increase of molecular weight compared to 
glucose, due to the high dimension of the fluorophore. 
In the works reported above, in vivo accumulation of 
this tracer seemed to reflect the presence of GLUT-
1 (as for FDG uptake) on cell membrane, even if this 
transporter is not the only factor that can influence probe 
uptake. In contrast, in 2012, another work [19] reported 
the incongruity between [18F]FDG-PET and NIR-
2DG imaging in a preclinical model of gastrointestinal 
stromal tumor (GIST). GIST bearing mice were treated 
with nilotinib, a c-kit inhibitor used in clinical practice 
that blocks glucose metabolism, and were monitored 
for 18F-FDG and NIR-2DG uptake. Images proved that 
fluorescence imaging with NIR-2DG probe did not 
change after treatment compared to the control groups. 
Conversely, 18F-FDG uptake, as expected, was found 
significantly reduced after nilotinib treatment showing 
the lack of correlation in the images provided by the two 
tracers. These findings indicated that NIR-2DG was able 
to detect tumors, but was not correlated to metabolic 
status. Despite this limitation, NIR-2DG fluorescent probe 
may be useful for assessing tumor bulk, even if it cannot 
substitute 18F-FDG PET in the study of tumor metabolism 
in response to treatment. For in vivo evaluation of lipid and 
amino acid metabolism, alternatives to nuclear imaging 
are not currently available. 
Proliferation
Proliferation is a tightly regulated process, which 
involves several proteins able to activate or block the 
cell cycle progression. Most tumor cells lose this fine 
regulation resulting in an abnormal neoplastic tissue 
growth [20]. Proliferation rate has been proposed 
as a biomarker for tumor grade, aggressiveness and 
tumor response to treatments [21-22]. Ki67 is the main 
biomarker used to ex vivo assess proliferation rate in 
immune histochemical analyses. 
In the clinical setting, PET imaging with [18F-FLT] 
(3’-deoxy-3’-fluorothymidine) [23] is used to non-
invasively monitor tumor cell proliferation, for example 
in the assessment of treatment. This tracer reports on 
Thymidine kinase activity in the salvage nucleotide 
biosynthesis pathway, providing an indirect evaluation 
of proliferation rate. Despite their clinical use and 
advantages, thymidine analogs have some pitfalls, such as 
the asynchronous cell cycle of tumor cells, the a-specific 
uptake by bone marrow, and the de novo thymidine 
pathway utilization, that might underestimate the real 
proliferation index [24-25]. 
To facilitate the study of tumor proliferation in 
pre-clinical models, overcoming the problems associated 
with the use of thymidine analogues, two novel 
fluorescent probes have been developed. The first one, 
the BombesinRsense680, generated by PerkinElmer, 
comprises a 7-amino acid bombesin peptide analog, 
a NIR fluorophore and a molecule to stabilize its 
plasma availability. This probe is designed to bind to 
the Bombesin specific receptor which is involved in 
stimulation of cancer cell proliferation. In fact, bombesin 
peptides act as autocrine growth factors, inducing either 
calcium mobilization or proliferation in tumor cells. This 
probe showed a significant accumulation in subcutaneous 
xenografts of colorectal HT-29 implanted in nude mice, 
with pancreas, skin and glands as secondary sites of 
uptake, due to endogenous expression of Bombesin 
receptor. It is characterized by short half-life in blood 
due to rapid clearance via kidneys and bladder [26]. The 
second commercially available proliferation probe for 
fluorescence imaging is called Tetra and was developed by 
Carestream Molecular Imaging (Carestream Health, Inc., 
Rochester, NY, USA) [27]. As showed by the company, 
the probe localizes in the tumor mass as demonstrated 
by its co-localization with X-SIGHT760 dye-labeled 
tumor cells. However, up to now, no elucidation about 
mechanism of action or its target has been provided and 
no in vivo studies using this probe have been published.
Due to the continuous proliferation, cancer cells 
have an incessant need of nucleotides for DNA synthesis. 
The folic acid (FA) is required for nucleotides synthesis, 
and in this view, Folate Receptor (FR) have acquired 
importance as target to image cancer proliferation by 
nuclear techniques [28-30]. In fact, the FR-α isoform is 
overexpressed in different human cancer tissues (such as 
ovary, lung, breast, kidney, brain, endometrium colon and 
hematopoietic cells of myelogenous origin; normal cells 
are instead very restricted in possessing folate receptor) 
[30], and it permits to folate analogue, such as the labeled 
probe, to enter the cells by endocytosis. Moreover, the 
labeling of receptor ligands doesn’t affect their affinity 
for the receptor, and being small molecules, they have the 
great advantage to show a complete penetration of solid 
tumors and rapid clearance from FR-negative tissues [30]. 
In addition to PET and SPECT derivatives, folate 
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was also labeled with near infra-red (NIR) fluorescent 
molecules, to perform fluorescence imaging (FLI) in 
preclinical setting. Among NIR fluorophores, the most 
used is indocyanine green (ICG), that in addition to its 
NIR fluorescent emission, it is the only dye that has 
been approved by the United States Food and Drug 
Administration for noninvasive NIR-fluorescence 
imaging for clinical application (to determine blood 
flow, to perform ophthalmic angiography, and to evaluate 
sentinel lymph nodes [31-32]). In order to study by FLI 
the expression of folate receptor (and as a consequence, 
the proliferation process), FA was conjugated with ICG in 
different designs [33-34]. In general, ICG-FA conjugates 
showed uniform accumulation in FR positive tumors 
and the probes were visualized until 24-48 hours. A 
background signal at the level of liver and urinary tract 
was also detectable only at early time points after probe 
injection, probably due to clearance of unbound probe. 
Despite the wide medical application, ICG 
has several drawbacks (due to its physicochemical 
characteristics) that limit its use in the clinic [35-36]. In 
short, ICG is prone to aggregate and degrade in aqueous 
solution and has a short half-life even when stored in 
the dark (t
1/2
 = 16.8 ± 1.5 h at 22°C); it binds to plasma 
proteins when administered intravenously and has a blood 
circulation half-life of only 2-4 minutes; in addition, ICG 
doesn’t permit an easy conjugation with proteins. In an 
effort to improve the stability and circulation half-life 
of ICG, it was enclosed into nanoparticles (NPs) [36], 
such as FA-ICG-PLGA-lipid NPs. When injected, these 
NPs localized only in tumor masses, whereas un-targeted 
probes (such as ICG-PLGA-lipid NPs) or ICG alone 
primarily localized at intestine level. After 24 hours, in 
vivo fluorescent signal was detectable only in tumors 
of FA-ICG-PLGA-lipid NPs injected mice. Moreover, 
several nanoparticles targeting FR were developed [37-40] 
using different fluorophores, and providing similar results. 
Despite the availability of these probes, 2DG is used 
as surrogate marker for both glucose metabolism and for 
proliferation, since an increase in cell number is correlated 
with an increase of glucose consumption.
Hypoxia
Another crucial process for many aspects of tumor 
development and growth is hypoxia. It has been indicated 
as a negative prognostic biomarker involved in chemo and 
radio resistance, and in tumor progression, as well as in 
the sustainment of the stem cell niche [41]. The key player 
of cell response to hypoxia is the hypoxia-inducible factor 
(HIF) [42-43], that induces the expression of different 
genes involved in neo-angiogenesis, vascular modelling, 
invasiveness, genomic instability and resistance to 
apoptosis, resulting in malignancy increase and reduction 
of chemo and radio treatment efficacy [44].
A recent and promising smart probe has been 
developed by PerkinElmer to study in an easy manner 
hypoxia in solid tumors and is commercially available: 
the HypoxiSense680. It is a Carbonic Anhydrase IX 
(CAIX) targeted fluorescent molecule used to visualize 
CAIX overexpression in tumors in response to regional 
tumor hypoxia [45-46]. The use of HypoxiSense680 
allows the non-invasive imaging and the quantification of 
tumor sub-regions undergoing hypoxia-related changes. 
HypoxiSense680 clears from the bloodstream quickly, 
with a half-life of approximately 12 hours, whereas at 
the tumor site it accumulates within hypoxic regions 
with a half-life of 6h. Tumor hypoxia can be detected as 
early as 3h post-injection, with optimal signal to noise 
ratio measured at 12-24h, once the circulating agent 
has completely been cleared. In a recently published 
work by our research group, we used HypoxiSense680 
as a biomarker of HIF-1 activity after treatment with 
Temozolomide (TMZ) in a mouse model of human glioma 
(U251 cell line). Cells were expressing Luciferase under 
control of HIF-1 activity and mCherry under a constitutive 
promoter. Obtained results demonstrated a correlation 
between HIF-1 activity and probe uptake by the tumor 
as expected since the presence in the CAIX promoter of 
Hypoxia Responsive Elements. These promoter sequences 
are recognized and bound by activated, nuclear HIF-1, 
inducing the transcription and further translation of the 
CAIX protein [47] as one of its targets. Our data, based 
on the use of this probe, showed a reduction of HIF-1 
activity after TMZ treatment of the glioma model. In this 
context, also HypoxiSense680 uptake was statistically 
reduced 2 days after the beginning of TMZ treatment, 
and this reduction was strongly maintained after 1 week. 
These data correlated with Luciferase signal, showing 
a reduction of HIF1-driven Luciferase expression soon 
after 2 days of treatment; conversely, the constitutively 
expressed mCherry reporter, used as indicator of viability, 
showed a signal reduction only one week after the 
beginning of the treatment. Also immunohistochemistry 
(IHC) analysis showed that CAIX protein expression 
was decreased in glioma tissues in TMZ treated mice 
validating non-invasive imaging results. Additionally, IHC 
documented a concomitant delocalization of HIF-1 from 
the nucleus to the cytoplasm, confirming transcriptional 
regulation described by Optical imaging technique and 
the relation between HIF-1 transcriptional activity and 
CAIX expression. In this context, the identification of 
CAIX as a non-invasive quantitative biomarker of HIF-
1 activity would support timely monitoring of tumor 
response to treatment. Furthermore, the use of this glioma 
model (U251-HRE-mCherry) would enable the in vivo 
assessment of novel specific CAIX probes for translational 
imaging procedures, making CAIX a promising 
theranostic imaging biomarker. 
Recently, the feasibility was studied to use 
dual-emissive materials to combine fluorescence and 
phosphorescence to detect oxygen level and, as a 
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consequence, hypoxia phenomenon. The first in vitro 
study was carried out on a cyanine dye conjugated with 
an O
2
-sensitive Pt porphyrin phosphor in a sol-gel matrix 
[48]. The possibility to combine a single component dye-
polymer with both fluorescence and phosphorescence 
offers some advantages over the classical three mixtures 
(dye, ligand and linker), and among all, the stoichiometric 
rate between fluorophore and phosphor provides sample 
homogeneity and minimal dye leaching. The iodide-
substituted difluoroboron dibenzoylmethane-poly-lactic 
acid (BF2dbm(I)PLA) sensor material holds these 
characteristics. Fluorescence emission depends only on 
molecular weight of the probe: high molecular weight 
samples are characterized by blue shifted emission, 
while low molecular weight samples show red shifted 
fluorescence. Conversely, phosphorescence is present at 
different level relative to O
2
 concentration. The probe was 
injected in a mouse bearing 4T1 mammary carcinoma 
[49], and the differences in phosphorescence emission was 
recorded by intravital microscopy imaging, after changing 
O
2
 concentration in breathing gas. The probe showed 
excellent contrast between the vessels and the tumor mass, 
with an increase in phosphorescence emission in presence 
of high level of O
2
.
Angiogenesis
Angiogenesis is defined as the formation of new 
vessels from pre-existing vasculature and in tumor 
progression it is a fundamental process for the local 
expansion of tumor colonies. When tumor increases its 
size, the diffusion of nutrient and oxygen in tumor mass is 
no longer efficient and new vessels are formed to supply 
this deficiency (e.g. tumor hypoxia, HIF-1α nuclear 
expression levels and de novo angiogenesis are recognized 
interconnected events in cancer). Being a hallmark of 
cancer, the possibility to detect angiogenesis could help in 
the diagnosis and in the planning of cancer therapy [50].
Angiogenesis is also a key process for metastasis 
formation, because it determines the formation of 
fenestrated vessels that facilitate the spreading of tumor 
cells to distant sites. As a consequence, angiogenesis 
could be considered as an additional marker for metastatic 
potential.
Two targets for angiogenesis have been successfully 
imaged in humans and mice: the VEGF and its receptor 
and integrin αvβ3.
VEGF and its receptor
Vascular endothelial growth factor (VEGF) [51] is 
a glycoprotein that acts as key mediator of angiogenesis 
induction: it binds to VEGF receptor 1 and 2, which are 
expressed on vascular endothelial cells, and normally are 
involved in embryonic development and wound healing. 
In cancer cells, VEGF production is up-regulated by 
mutation in oncogenes, hypoxia establishment and growth 
factor over-activation, resulting in the “angiogenic switch” 
[51], characterized by new vasculature formation and 
exponential growth of the tumor. The new vessels are 
structurally and functionally abnormal: they are irregular, 
twisted, hemorrhagic and not organized, having also dead 
Table 2: List of RGD-based probes
rGD motif Fluorophore Other label Tested in reference
Cypate-linear-RGD linear Cypate A549 lung adenocarcinoma [56]
IrD800-linear-rGD linear IRD800 U87MG, RCAS-PDGF and TS543 glioblastoma [58]
IRD800-cyclic-RGD cyclic IRD800 U87MG, RCAS-PDGF and TS543 glioblastoma [58]
Cy5.5-cyclicRGD cyclic Cy5.5 U87MG glioblastoma [57]
CLIO-Cy5.5-cRGD cyclic Cy5.5 CLIO BT20 mammary carcinoma [64]
QD705-RGD cyclic QD U87MG glioblastoma [67]
111In-DtPA-IrD800-rGD cyclic IRD800 111In M21 melanoma [68]
Integrin trace dimer ICG www.intrace-medical.com
Cy7-tetrameric RGD tetrameric Cy7 U87MG glioblastoma [59]
RAFT-RGD-Cy5.5-SS-Q tetrameric Cy5.5 IGROV-1 ovarian cancer [60, 61]
64Cu-DOTA-Cy5.5-RGD-
knottin knottin Cy5.5
64Cu
MDA-MB-435 mammary 
carcinoma and U87MG 
glioblastoma
[69]
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ends. The result is a sub-optimal blood flow that increases 
hypoxia which determines further VEGF production, 
validating VEGF as a target for therapy. 
Human VEGF has been conjugated with NIR 
fluorescent dye Cy5.5 (Cy5.5-VEGF), yielding a unique 
functionally active probe for in vivo molecular imaging 
by FLI. This molecule has been tested and validated in a 
subcutaneous murine model of mammary tumor [52]. 
Development of a mAb-based dual functional 
imaging agent, containing both NIR fluorescent molecules 
and a PET radionuclide, could facilitate the translation of 
FLI imaging into the clinical setting, providing synergistic 
advantages over a single imaging modality. For example, 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA) chelator was conjugated with amine-
functionalized semiconductor quantum dots (QDs) and 
VEGF protein and was further labeled with 64Cu (64Cu-
labeled DOTA-QD645-VEGF) [53] permitting to carry 
out fluorescence and PET imaging. Both NIR fluorescence 
imaging and microPET showed VEGFR-specific delivery 
of conjugated DOTA-QD-VEGF nanoparticles; good 
correlation was also observed between the images and ex 
vivo PET and NIR fluorescence organ imaging. 
Changing strategy, Bevacizumab, a monoclonal 
antibody able to detect VEGF, was labeled with 
IRDye800CV, a near infra-red fluorophore (Bevacizumab-
IRD800), and tumor uptake was evaluated in human 
xenograft-bearing athymic mice (injected with ovarian 
cancer cell line A2780, expressing high level of VEGF) 
during 1 week after tracer injection [54]. Images showed 
high signal- to- noise ratio in the tumors at day 2, and it 
remained constant until day 6. Given its specificity, it was 
also tested in an intraoperative setting in two models: a 
primary ovarian cancer and an intraperitoneal metastasis 
model of gastric cancer. In both studies the probe allowed 
to visualize tumor mass or metastasis. In the latter case the 
peritoneal cavity was open, whereas the primary ovarian 
tumor was detectable in spite of the presence of intact skin 
overlying the tumor. These findings strongly support future 
clinical application of NIR fluorescence-labeled tumor-
specific antibodies in a wide range of clinical applications, 
including intraoperative image-guided procedures.
Integrin
Integrin is a family of cell adhesion molecules 
that are involved in a wide range of interaction between 
cells and extra-cellular matrix. For example, the isoform 
αvβ3 is differently expressed in new-born vessels and in 
tumor cells compared to normal tissues and endothelial 
cells, making it eligible for tumor imaging as well as 
for anti-neoplastic treatment [55]. This integrin strongly 
correlates with tumor progression and invasion in a 
variety of neoplasms (such as glioma, breast, ovarian and 
prostate cancers and melanoma), facilitating the spreading 
of cancer cells through blood vessel. The possibility to 
investigate αvβ3 biodistribution could be a reliable method 
to study the relation between endothelium and tumors, 
since angiogenetic switch is correlated with endothelial 
cells and with their tube-forming capacity.
Integrin αvβ3 binds to a wide range of extracellular 
matrix proteins (e.g. vitronectin, fibrinogen, laminin, 
collagen) characterized by an Arg-Gly-Asp (RGD) 
triple-peptide motif, and different probes based on RGD 
domains starting from linear [56] to cyclic [57-58] (both 
available from LI-COR Biotechnology - GmbH, Bad 
Homburg, Germany), to multiple peptides [59-61] were 
developed to improve the targeting capability and its 
affinity, to prolong the circulation time and to decrease 
the tumor washout rate. These peptides were labeled with 
different fluorescent molecules in order to in vivo study 
αvβ3 biodistribution in tumors (see Table 2 for a full list of 
the different strategies for probe development). 
For example, through a RAFT platform, capable 
of building scaffold molecules [62], a cyclic decapeptide 
forming a ring with two faces was generated. The upper 
face was used to link four copies of the RGD peptide, and 
the bottom face was conjugated with the Cy5.5 fluorophore 
and a quencher, making the probe un-fluorescent until 
the reduction of the disulfide bond (SS) during integrin 
mediated internalization, thus providing higher signal 
specificity. The probe was called RAFT-RGD-Cy5.5-SS-Q 
and was tested in IGROV-1 ovarian cancer models [60-
61], showing good tumor contrast from 3 to 24 hours, with 
a peak at 10 hours. 
The use of small, structurally simple RGD 
peptide-based tracers has some disadvantages. They 
are characterized by low tumor uptake due to the rapid 
tumor washout depending upon the sub-optimal receptor-
binding affinity and the inadequate contact with cell-
surface integrin receptors [63]. Even if dimeric RGD 
peptide tracers had some advantages over linear RGD, 
their tumor accumulation resulted not to be optimal as 
well. Conversely, the development of tetrameric tracers 
has resulted in high receptor-binding affinity, due to the 
higher molecular size of these tracers, determining longer 
blood circulation time responsible for the prolonged tumor 
retention [63].
Cy5.5-cyclicRGD was also linked to CLIO 
nanoparticles (containing an icosahedral core of 
superparamagnetic crystalline Fe
3
O
4
 -magnetite-), 
CLIO-Cy5.5-cRGD [64], forming a magneto-fluorescent 
nanoparticle for multimodal imaging of αvβ3 integrin. 
Nanoparticles used as targeted agents offer the advantage 
of signal amplification by being able to be loaded with 
several molecules of both peptide and fluorophore 
[65-66]. Moreover, they have the advantage of more 
efficient targeting of the αvβ3 integrin expressed in 
tumor endothelium (neo-vascularitation) and of selective 
delivery of drugs or other molecules in loco. Probe uptake 
was assessed in mice implanted with mammary carcinoma 
cell line BT20. When tumor reached 3-4 mm of diameter, 
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mice were injected with CLIO-Cy5.5-cRGD or with 
CLIO-Cy3.5-linearRGD, as control. Both compounds 
showed high fluorescent signal in liver and spleen, but 
only the cyclicRGD containing nanoparticles showed 
high specific signal in BT20 cells. Since the half-life of 
the molecule was 180 minutes, fluorescence imaging at 
early time point showed the presence of nanoparticles 
in the vasculature, while after 1500 minute, fluorescent 
signal reflected the specific accumulation at the tumor site, 
with a different enhancement for deep tumor slices. Also 
MRI images demonstrated a T2 signal at tumor level. The 
CLIO-Cy5.5-cRGD nanoparticles were readily detectable 
by fluorescence-based imaging and MR-based imaging at 
a dose of 3 mg/kg Fe, which is compatible with human 
use.
RGD peptides were also used to functionalize 
Quantum Dots (QDs) made of cadmium selenide cores 
overcoated with a layer of ZnS (which emits at 705 nm, 
and represents the best fluorophore among all QDs, even if 
its toxicity has not yet been well defined), and it has been 
called QD705-RGD [67]. 
Furthermore, RGD peptides were also labeled with 
IRD800 fluorochrome and 111In (111In-DTPA-IRD800-
RGD [68]) or with Cy5.5 and 64Cu (64Cu-DOTA-Cy5.5-
Figure 3: In vivo detection of Luciferase activity in orthotopic U251-HRE-mCherry glioma models and ex vivo validation. 
A. 2-D luminescence (rainbow scale) and fluorescence (red-yellow scale) images of U251-HRE-mCherry tumors in control and TMZ-
treated mice at different time points. The last column is the representative 2-D images of TMZ treated mice injected with HypoxiSense680 
at different time points during TMZ treatment. Images are presented with the same scale bar. b. Ex vivo immunohistochemical staining 
CAIX in control and treated mice. TMZ=Temozolomide; CAIX=Carbonic Anhydrase IX.
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RGD-knottin [69], in which RGD was grafted into knottin 
[70], a cysteine knot peptide, identified from a library of 
genetically modified knottin peptides able to target αvβ3, 
αvβ5 and αvβ1 integrins), in order to perform a multimodal 
analysis of integrin expression by optical and nuclear 
imaging. 
Lastly, a non-peptidic probe capable of targeting 
αvβ3 integrin in neo-vasculature (Perkin Elmer), called 
Integrisense [71], is commercially available and has 
been labeled with NIR emitting (645, 680 or 750 nm) 
fluorophores. Integrisense680 was injected in mice bearing 
either αvβ3-positive tumor (HCT116 cell line derived form 
a colorectal carcinoma or A673 derived from an Ewing’s 
sarcoma) or αvβ3-negative but αvβ5-positive tumor (HT29 
- colorectal adenocarcinoma): imaging showed a stronger 
signal in αvβ3-positive tumors, compared to HT29 αvβ3-
negative tumors, 4-24 hours post-injection. This difference 
in accumulation was ascribed to the expression of 
different integrins. When an excess of un-labeled parental 
compound was injected, a reduction in accumulation of 
Integrisense680 in αvβ3-positive tumor was observed; 
moreover, after treatment with Avastin (a humanized 
anti-VEGF monoclonal antibody -bevacizumab- able 
to inhibit growth of rhabdomyosarcoma in mice) the 
Integrisense680 uptake significantly dropped down. These 
findings validated the specificity of the signal obtained 
with this probe, and its high affinity for the target.
In addition to the use of αvβ3 integrin as molecular 
target for the study of neoangiogenesis, other tracers were 
developed targeting α
2
, α
3
 or α
4
 integrin by conjugation of 
specific peptides with Cy5.5 or AlexaFluor680 molecules 
[72-76] and these probes were visualized in different 
murine models of prostate, ovarian and breast cancer and 
lymphoma by optical imaging. 
Since angiogenesis and hypoxia are strictly related 
within the context of tumor growth and progression 
(angiogenic switch), we started studying these two events 
by using specific fluorescent probes in a mouse model of 
glioblastoma [45-46] (Figure 4). This tumor cell line has 
been engineered to express Luciferase reporter gene under 
control of HRE (Hypoxia Related Element) sequence, as 
described above in paragraph 2.3, becoming a biomarker 
for HIF-1 activity also in the context of hypoxia 
establishment. This model has been used to assess the 
ability of Hypoxisense680 and Integrisense750 to monitor 
hypoxia establishment and neoangiogenesis, respectively, 
in relation to tumor growth. Luciferase activity has been 
used as internal control of HIF-1 activity involved in 
hypoxia establishment as already demonstrated elsewhere 
[45]. Figure 4 shows that HIF-1 activity increased with 
tumor growth during time and Hypoxisense680 confirmed 
hypoxia establishment as indicated by Luciferase 
activity increase. Consequently, as can be expected, 
Integrisense750 probe signal also incremented in relation 
to neoangiogenesis within the tumor lesion, probably 
as a consequence of HIF-1 activity increase in hypoxic 
regions and its effect on specific target genes involved in 
this process.
From the technical standpoint, this example is 
very interesting because it demonstrates the possibility 
of monitoring two different tumor aspects (hypoxia and 
neoangiogenesis) by using two different probes co-injected 
in the same mouse model. The different wavelength 
of the probes allows to distinguish (un-mix) the two 
different signals obtaining two image sets each specific 
to a different wavelength. Images can be also shown as 
a single image set to assess the co-localization of the two 
fluorophores. In this example, moreover, the possibility to 
assess HIF-1 activity also by measuring Luciferase activity 
allowed to use it as an internal control of tumor viability 
and, since day 18 after injection, of hypoxia establishment. 
Luminescence can be used to compare the signal obtained 
with the fluorescent probes, allowing to characterize newly 
produced probes, in view of their optimization.
Invasiveness
Invasion entails the dissemination of tumor cells in 
the local microenvironment, whereas the term metastasis 
refers to the dissemination of tumor cells to distant organs 
through lymphatic or blood vessels; these are the most 
insidious and life-threatening aspects of cancer, and 
constitute the evidence of increasing tumor malignancy. 
Invasiveness and metastatic potential are supported by the 
up-regulation of specific proteases, such as cathepsins and 
metalloproteinases, which facilitate tumor cell invasion 
in the extracellular matrix [77]. The involvement of these 
proteins in the invasion and metastatic process highlights 
the importance of protease imaging for the assessment of 
tumor grading and the estimation of its metastatic potential 
in relation to treatment set up and evaluation as well. 
Cathepsins
Cathepsins are proteases involved in different 
step of invasiveness [78]: first, they are involved 
in the degradation of vascular basement membrane 
during angiogenesis; second, they are implicated in the 
dissolution of cell-cell junctions and degradation of both 
the epithelial basement membrane and the extracellular 
matrix to allow cancer cells to spread from the primary 
tumor mass; third, intravasation of cancer cells into the 
blood or lymphatic circulation, and their extravasation in 
distant organs require the activity of these proteases. 
In particular, cysteine cathepsins are proteolytic 
enzymes, consisting of 11 members: cysteine cathepsin B, 
C, F, H, K, L, O, S, V, W and X. They play an important 
role in cancer processes, and surveys in human tumors 
have suggested an association of certain cathepsins 
(especially B and L) with malignancy [79].
With the aim of studying the activity of these 
enzymes, activatable probes have been developed and 
called activity-based probes (ABPs). These probes 
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are usually formed by three components: a reactive 
functional group known as a warhead for the specific 
enzyme targeting (in this case, the cathepsin), a linker 
for preventing steric congestions, and a reporter tag 
for visualization of the probe localization [80-82]. The 
possibility of using fluorescent molecules to label the 
probe opens the possibility to in vivo study the activity of 
cathepsins by optical imaging.
GB137 [83] is an example of this kind of probes, 
and was developed by using acylomethil ketone (AMOK) 
as warhead for enzyme activity detection (other probes 
were developed by linking fluorophores to different 
polymers for detection of cathepsin B [84] or K [85]). In 
this probe, the fluorophore Cy5.5 and the quencher QAY21 
are linked to the structure, and the reaction between 
cathepsin B and L and AMOK determines the cleavage of 
the interaction between the quencher and the fluorophore, 
which becomes capable of emitting fluorescence. This 
probe was intravenously injected in breast cancer bearing 
mice, and the non-invasive, whole-body imaging allowed 
the direct monitoring of cathepsin activity in tumor and 
spleen, kidneys and liver (all organs where cathepsins 
B and L were expressed), and showed no background 
since the earliest time point (conversely, the use of the 
same probe without the quencher resulted in a general 
background until 12 hours after injection). The specific 
signal in tumor increased over time, reaching a peak at 
6-8 hours post-injection. To validate the specificity of this 
signal, a blocking study was performed using K11777, 
an inhibitor that blocks the active sites of all cysteine 
cathepsins, showing a decrease of fluorescent signal of 
60-80% in treated animals respect to controls [83]. These 
results suggested NIRF-ABPs as potentially valuable new 
imaging agents and powerful tools for preclinical testing 
of therapeutic agents in vivo.
An easy and powerful way to study the cathepsin 
modulation is the use of ProSense680 fluorescent probe, 
already commercially available (PerkinElmer) [86-87]. 
It is a protease-activatable fluorescent agent useful for 
in vivo studies, which is activated by proteases such as 
Cathepsin B, L, S and Plasmin, and it is also scheduled to 
enter clinical trials in the coming years for the detection of 
ovarian and colorectal cancer. ProSense is optically silent 
in its un-activated state and becomes highly fluorescent 
following protease-mediated activation. This probe was 
injected in mice bearing different types of tumors (such 
as ovarian [88] and hypopharyngeal cancer [87]), and 
provided a strong correlation among fluorescent signal of 
ProSense680, cathepsin activity and tumor size. Moreover, 
the Prosense680 was visualized with laparoscopic 
Figure 4: Optical imaging assessment of hypoxia and neoangiogenesis levels. Mice were injected with an engineered 
glioblastoma line expressing Luciferase under the control of a HIF-1 inducible promoter. Images represent HIF-1 activity (Luciferase 
activity), hypoxia establishment (Hypoxisense680) and neo-angiogenesis (Integrisense750) during time, and show an increase of both 
hypoxia and angiogenesis deeply related to HIF-1 activity.
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microscopy [86] in ovarian cancer in mice and ex vivo in 
human explanted tissues. This approach may be translated 
into the clinical setting for endoscopic high resolution 
detection of initial ovarian cancer, instead of classical 
biopsies [86].
Another important class of protease in cancer is the 
serine proteases, and in tumor, cathepsin D and E have 
gained a great importance. 
For example, cathepsin E is a tumor associated 
intracellular non-lysosomal aspartic proteolytic enzyme, 
and its expression was observed in several tumors. 
cathepsins E was labeled with a NIR fluorochrome 
[89] (Cy5.5-DPGC-CathE) combined with a quencher 
(DPGC). The probe was injected in cathepsins E-positive 
MPanc96-E human tumor bearing mice and the probe 
localization was followed by fluorescence imaging. 
Images showed a clear signal at tumor site starting 24 
hours after probe administration. The signal increased 
up to 72 hours, and tumor border visualization became 
very clear. A high fluorescent signal was also present 
in the upper quadrant of abdominal cavity, due to the 
liver ability of retaining molecules with high molecular 
weight, including the probe, and due to its high enzymatic 
physiological activity, including also cathepsin activity, 
which induced probe activation. 
In summary, due to the central role of cathepsin 
in tumor progression, their visualization represents a 
valid target for tumor identification and/or for evaluating 
treatment effect. 
Matrix metalloproteases
Matrix metalloproteases (MMPs) are a family of 
neutral metalloenzymes secreted as latent pro-enzymes 
that could be used as target for the metastatic process. 
MMPs require activation through proteolytic cleavage 
of the amino-terminal domain, and their activity depends 
on the presence of cofactors such as Zn2+ and Ca2+. 
Increase in MMP activity has been found to be correlated 
with invasion and metastatic potential in a wide range 
of cancers [90], and in this view, the possibility to non-
invasively image MMP activity becomes an important 
theragnostic biomarker of tumor behavior. Two different 
types of probes were developed for non-invasive 
assessment of their activity through Fluorescence imaging: 
the first group is constituted by specific target molecules 
for different MMPs, conjugated with a fluorophore or also 
a quencher, the second group by MMP specific inhibitors.
In the category of target peptides, among the 
commercially available activatable probes, there is a FAST 
(Fluorescent Activatable Sensor Technology) probe, called 
MMPSense (PerkinElmer) [87]. It is a MMP activatable 
agent that is optically silent upon injection and produces 
fluorescent signal (due to the conjugation to 645-, 680- or 
750-fluorochrome) after cleavage by MMPs. Activation 
can occur by a broad range of MMPs, including MMP 
2, 3, 7, 9, 12, and 13. This activatable architecture offers 
high target specific signal with reduced background even 
if, in some cases, the substrate can be cleaved by other 
enzymes making the reaction, and the imaging data, non-
specific. To describe MMPSense680 specificity, it was 
injected in subcutaneous hypo-pharyngeal squamous 
cell carcinoma bearing mice. A clear signal localized in 
the tumor edge (where metalloproteinase activity was 
expected) was detectable, whereas signal due to 2DG 
uptake, used to detect metabolically active tumor mass, 
was predominantly located at the core of this ring. Ex 
vivo histology showed that MMPsense fluorescent signal 
and MMPs (detected by immunohistochemical approach) 
co-localized in the tumor directly surrounding tissue 
(also named “invasive tumor border”), where MMPs are 
involved in the extracellular matrix degradation for tumor 
invasion. 
Another probe that can be used for the MMP 
activity imaging is the MT1-MMP fluorogenic probe. It 
is composed by a NIR dye (Cy5.5), a MMP substrate, and 
a quencher (BHQ-3) [91]. It has been reported that MT1-
MMP is retained for a long time in melanoma tumor cells 
and strong fluorescent signal in tumors is due to the action 
of different types of MMPs, such as MMP-2 and MMP-9. 
Its specificity in enzyme targeting has been demonstrated, 
since the injection of MMP-I, an inhibitor of different 
MMPs, produced a strong reduction in probe signal. 
A MMP2 specific probe was developed to 
distinguish cancer foci (delineating the primary tumor 
in malignant glioma, medulloblastoma, prostate and 
intestinal cancer, sarcoma, as well as metastatic cancer 
foci) from adjacent normal tissues: the chlorotoxin:Cy5.5 
(CTX:Cy5.5) [92]. This probe is based on the use of 
chlorotoxin (CTX) [93], that was demonstrated to show a 
preferential targeting for cancer cells [94-95]. For optical 
imaging, CTX was labeled with Cy5.5: this molecule is 
able to bind to a lipid raft-anchored complex that contains 
MMP-2 [96], and it is internalized within the cells [97]. 
In this paper, authors showed specific probe accumulation 
in the cerebellum of a transgenic mouse model of 
medulloblastoma, and CTX:Cy5.5 signal was also 
detected in primary tumors and metastasis during intra-
operative surgery carried out in prostate and intestinal 
cancer, and sarcoma bearing mice. The imaging data 
were validated by IHC analyses, showing that portions 
of tissues characterized by Cy5.5 signal resulted to be 
cancerous, whereas adjacent non-fluorescent tissues were 
normal. This exquisite resolution and the safety of CTX-
based probe make the use of this probe conceivable for 
pre-clinical investigation and a possible future translation 
in the clinical setting (at least for the superficial lesions). 
MMP-2 (gelatinase, found to be correlated to 
numerous cancer types and to poor outcome) was also 
targeted by direct conjugation of Cy5.5 or rhodamine 
with its specific target peptide (MMP-Cy5.5 [98] or 
MMP2-TMR, respectively) [99], and probe accumulation 
was monitored during time, showing the specificity of 
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the probe and identifying a sensitive method for the in 
vivo imaging of MMP-2 expression. Other probes were 
developed to target the specific activity of other MMPs, 
such as MMP-7 and MMP-13, by labeling their specific 
target peptides with Cy5.5 (MMP7-Cy5.5 [100] and 
MMP13-Cy5.5 [101], respectively). 
Opposite to this strategy, some probes such as 
MMP2-TIMP-Cy5.5 [102] or AF489-Cy5.5 [103] were 
developed to image MMP activity by using fluorescent 
synthetic low-molecular-weight MMP inhibitors capable 
of targeting specific pockets of MMPs. For example, 
Cy5.5-AF489 was injected in mice bearing different 
tumors (A-673 Ewing’s sarcoma, HT-1080 fibrosarcoma, 
MDA-MB 231 and BT20 breast cancer) and fluorescent 
signal was followed for up to 72 hours. Images showed 
different level of probe accumulation in different tumors, 
due to their different expression of MMP-2 and -9 (A-
673 >> HT-1080 > MDA-MB 231>> BT20 cell line), 
and A-673 tumors showed the higher signal. Time course 
imaging showed a clear and fast Cy5.5-AF489 signal 
already after 30-45 min. While signal in non-tumor 
tissues remained constantly low, tumor masses showed 
a signal increase during time, and tumor to background 
ratio reached a maximum until 6 hours. After 24 hours, 
the signal intensity decreased for all tumors, and after 72 
hours a still detectable signal was observed only in A-673 
and HT-1080 tumors. Comparing the Cy5.5 signal with 
MMP expression, a clear correlation was observed. To 
confirm the specific targeting of this probe, when A-673 
cell bearing mice were injected with parental un-labeled 
MMP inhibitor only a significantly lower signal, respect 
to non-treated tumors, was visualized. The probe was also 
compared with MMPsense750 in A-673 bearing mice, and 
both probes were able to detect MMP-positive tumors, 
with different time-windows: Cy5.5 signal was detected 
earlier in tumors (since 30 minutes, with a peak at 3 hours) 
than that of MMPSense750 (that showed a signal starting 
since 3 hours, with a peak at 24 hours). Thanks to small 
dimension of this kind of probes and their non-peptidic 
structure, the translation from pre-clinical to clinical 
studies might be possible. 
Inflammation
Inflammation is a protective response based on the 
intervention of immune cells, blood vessels and molecular 
mediators. As a rule it arises after microbial infection or 
Figure 5: Schematic representation of different Tumor Cell Biomarkers. The image shows the membrane localization of some 
molecules used as biomarkers, and the different possibilities to target them.
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trauma, with the aim to defend the host or to induce repair 
and regeneration of tissues, but it is also involved in the 
orchestration of tumor microenvironment, contributing 
to cancer cell survival, proliferation and migration [104-
105]. For example, chronic inflammation is a pathological 
condition that can lead to dysplasia and cancer; besides, 
some tumor types, such as ovarian or gastric cancer, are 
related to a previous microbial infection, such as HPV-
16 or Helicobacter pylori, respectively. In addition, 
infiltrating immune cells are usually observed in tumor 
lesions: some of these cells are related to a cytotoxic 
effector activity against tumor cells (e.g. CD8+ T cells, 
or Natural Killer cells) but other populations are involved 
in the stimulation of tumor progression (e.g. pro-tumoral 
macrophages M2); moreover, a gene expression profile 
correlated with inflammation was described in different 
tumors [104-105].
To study inflammation in animal models, different 
optical probes were developed
Xenolight Rediject COX-2 probe is a 
commercially available targeted agent, (Perkin Elmer), 
able to specifically detect, by fluorescence imaging, 
Cyclooxygenase-2 (COX-2) activity in tumors. Its 
efficiency has been described in murine models of colitis-
associated and sporadic colorectal cancer [106]. COX-2 is 
over-expressed in different kinds of tumors [107-108] and 
inflammatory tissues (at different levels), but not in normal 
cells. It is associated with all stages of cancer progression, 
and its amount increases with tumor malignancy [109]. 
It has been reported a strong correlation between COX-2 
dependent fluorescent signal acquired by Optical imaging 
and subcellular COX-2 expression as assessed by IHC 
at the level of implanted intestine tumor [106]. Optical 
imaging of COX2 activity might help in the identification 
of patients that would benefit from aspirin treatment as a 
preventive strategy against colorectal cancer development 
or in the visualization and detection of pre-neoplastic 
lesions during surveillance endoscopy. 
More recently, NANQ-IMC6 [110] probe was 
developed and permitted to study by fluorescence 
imaging the activity of COX-2 both in inflammation and 
cancers. This is an activatable probe in which the enzyme 
is necessary for the probe to become fluorescent. The 
probe is constituted by a chemical modification of COX-2 
substrate indomethacin (IMC), which was linked to nitro-
acenaphthenequinone (NANQ) fluorophore. The probe 
was injected in a murine model of sarcoma or in mice 
treated with carrageen to induce inflammation, and it has 
been shown that fluorescent emission is different between 
the two conditions, allowing to discriminate not only 
normal tissues from inflammation sites, but also different 
causes of inflammation. Based on these data, the use of 
this probe could be interesting to perform non-invasive 
differential diagnosis, or to guide, in real time (by using 
a hand-held ultraviolet lamp emitting at 365 nm), tumor 
resection during surgery.
Another example of probe for inflammation 
detection is the SLX-Lipo-Cy5.5 [111]. This probe 
is based on the use of Cy5.5 labeled Sialyl-Lewisx 
carbohydrate, normally present on leucocyte surface, able 
to bind E-selectin. This molecule is expressed in inflamed 
tissues in response to Tumor Necrosis Factor α and 
Interleukin-1 that are released as a result of inflammatory 
stimuli. By targeting E-selectin it is possible to study the 
site of inflammation: experiments carried out in mice 
bearing Ehrlich ascites tumor cells showed SLX-Lipo-
Cy5.5 signal at 24 hours post injection, with a peak at 48 
hours (Lipo-Cy5.5 or G4GN-Lipo-Cy5.5 were used as 
controls, and no fluorescent signal was observed in tumor 
regions).
Alternately, macrophages have been labeled with a 
macrophage-specific fluorescent probe (MFP) [112]: MFP 
selectively allowed the visualization of monocytic and 
macrophagic cell populations in vitro as well as in vivo. 
This probe might be used to visualize sentinel lymph nodes 
during imaging-guided surgery, highlighting abnormalities 
related to inflammation and tumor infiltration in real time. 
Another inflammation probe, used to monitor tumor 
invasiveness as well (see paragraph 2.5.1), is ProSense 750 
probe. This probe has been used to evaluate inflammation 
associated to intestinal lesions in a mouse model of 
hereditary polyposis [113], reporting that probe activation 
correlated with the local density of pro-inflammatory cells 
infiltrating the lesion and with the amount of associated 
active enzymes at the tumor site.
A novel dual probe has been developed to study 
inflammation in a multimodal way by FLI and MRI 
(PFC-NIR dual-mode agent, PerFluoroCarbon-Cy5.5 
probe) [114]. Breast carcinoma cell (4T1) bearing mice 
and naïve control mice were intravenously injected with 
the probe, and imaging was performed over time. The 
tumors were detectable in FLI images approximately six 
hours post-injection. No NIR signal was detected in the 
same region of control animals or on the contralateral 
flank of tumor bearing mice. A-specific NIR signal was 
also detected in the abdomen (liver and spleen), in both 
healthy and 4T1-derived tumor-bearing mice two hours 
post-probe administration. PFC has been also used to label 
macrophages [115-116], and it has been demonstrated that 
host phagocytes, recruited to the tumor microenvironment, 
represent the probe reservoir, rather than cancer cells. 
This has been confirmed by 19F MRI (7 Tesla). In fact, 
MRI images, thanks to the higher spatial resolution of 
this technique compared to optical imaging, revealed that 
inflammatory signal was located in the tumor periphery.
Another interesting strategy to study inflammation 
is the use of Xenolight Rediject Inflammation probe 
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(PerkinElmer). This probe is based on the use of luminol 
as chemiluminescent source, enabling the detection of, 
mainly, acute inflammation largely mediated by tissue-
infiltrating neutrophils, whose myeloperoxidase (MPO) 
activity is required for luminol bioluminescence [117]. 
Human HCT116 tumors were implanted in nude mice, and 
when tumor became visible, in vivo boosted splenocytes 
were intravenously injected into tumor-bearing mice. 
Bioluminescence imaging revealed inflammatory luminol 
bioluminescence 6 days after splenocyte transfer, showing 
neutrophil presence at tumor site. Mice were also injected 
with lucigenin [118], another bioluminescent probe for 
inflammation capable of being activated by macrophages: 
optical imaging displayed also lucigenin signal in the 
tumor. Control mice that did not receive conditioned 
splenocytes, showed no luminol or lucigenin signal at the 
tumor site. These two probes, by allowing non-invasive 
assessment of both neutrophil and macrophage-mediated 
inflammation, with no need of reporter gene expression, 
can be efficiently used in combination for the longitudinal 
in vivo evaluation of the inflammatory cascade in 
experimental models. 
Apoptosis
Apoptotic rate is another important tumor feature 
[119]. During tumor formation, mutation in oncogenes and 
alteration of cell processes may determine dysregulation 
of apoptosis reducing cell ability in inducing this pathway. 
On the other hand, tumor response to some anti-neoplastic 
treatments can result in an increase of the apoptotic cell 
rate [120]. Since the importance played by apoptosis 
(regulation and de-regulation) in tumor establishment, 
progression and treatment responsiveness, non-invasive 
apoptosis imaging provides important information for 
tumor characterization and management of the disease. 
Different probes were developed in order to 
visualize apoptosis, mainly based on the detection of 
phospohatidilserine (PS) translocation in the outer 
membrane layer and on caspase-3 activity.
Phospohatidilserine
PS is a membrane glycoprotein, normally 
maintained in the inner leaflet of the plasma membrane by 
enzymes called flippases. In apoptotic cells flippases do 
not translocate PS, that can thus be found in the external 
layer of the cell membrane. Annexin V, a cellular protein 
which is known to have an anticoagulative function [121], 
is able to bind to PS, targeting apoptotic process [122].
AlexaFluor750 [123] (AnnexinV750-Vivo, Perkin 
Elmer), Cy5.5 [124], IRDye [125] and Quantum Dots 
(QDs) [126] were used to label Annexin V, sometimes 
also in presence of gadolinium [126]. By using these kinds 
of probes, fluorescence imaging showed minimal probe 
uptake in non-treated mice, with only a low a-specific 
signal detected in the kidneys. Following the treatment 
with pro-apoptotic drugs (such as doxorubicin, cetuximab 
or cyclophosphamide), a strong signal in tumors of treated 
mice was observed. The availability of radionuclide 
labeled Annexin V allows an easier potential translation 
of preclinical results in the clinical nuclear-based imaging 
setting.
Even if labeled Annexin V is the most used probe 
for apoptosis studies, there are some pitfalls in its use, 
such as non-specific accumulation in liver and kidneys, 
reduced affinity for PS after labeling, and exposition of PS 
during necrosis as well, producing a non-specific targeting 
of programmed death process [127].
Caspases
Caspases play a central role in the transduction of 
Death Receptor apoptotic signals [128]. Caspases are 
highly conserved cysteine-dependent aspartate-specific 
proteases. There are two types of caspases: initiator 
caspases (caspase 8, 10, 9, 2), and effector caspases 
(caspase 3, 7, 6). The activation of initiator caspases 
requires binding to specific oligomeric adaptor protein; 
effector caspases are then activated by these active 
initiator caspases through proteolytic cleavage. The active 
effector caspases then proteolytically degrade intracellular 
proteins to carry out the cell death program.
Caspase 3 is activated by interaction with caspase 
8 and 9. The targeting of its activity is index of advanced 
apoptosis, and some probes have been developed to detect 
it.
An interesting probe for non-invasive fluorescence 
imaging of apoptosis based on Caspase 3 activity is the 
TCAPQ647 activable probe [129], in which the amino 
acid effector caspase recognition sequence, DEVD, was 
flanked by an AlexaFluor645 fluorochrome and a quencher 
(QSY21), and at its N-terminus was placed the amino 
acid permeation peptide sequence (RKKRRQRRRG), 
of the human immunodeficiency virus-1Tat (HIV-1Tat), 
necessary to allow the entry of the probe into the cells. 
In vivo characterization of this probe [130] showed an 
apoptosis correlated fluorescence emission in xenograft 
tumor models of colon cancer.
The tAB50-Cy5 and AB50-Cy5 probes [131] were 
labeled with Cy5.5 and developed to target both effector 
caspase 3 and 7, by using a common DEVD sequence, 
and a Tat or non-Tat peptide, respectively, for entering the 
cells. The caspase activation was monitored in xenografts 
of human colorectal cancer models in which the apoptosis 
was induced by treatment with the monoclonal antibody 
Apomab, a pro-apoptotic agonist of the Death Receptor 5, 
which causes apoptosis. Both probes permitted to detect 
the activity of both types of caspases in tumors, with 
different kinetics. The signal of tAB50-Cy5 probe was 
substantially brighter than that produced by the AB50-
Cy5 probe, but its clearance was slower, resulting in a 
lower tumor to background ratio for AB50-Cy5 probe, 
at least at early time points. These data highlighted the 
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possibility to noninvasively monitor apoptosis in tumors 
treated with chemotherapeutic agents using fluorescence 
based imaging strategies.
Another example of probe for the in vivo assessment 
of apoptosis through caspase activity targeting is the PPB 
probe [132]. PPB is formed by a ligand for folate receptor 
capable of targeting tumor cells, an infrared fluorochrome 
pyropheophorbide α (Pyro), a black hole quencher 3 
(BHQ3), and a peptide linker (GDEVDGSGK) specific 
for caspase-3 (in fact it contains the tetrapeptide motif 
DEVD for caspase-3 recognition). Thanks to the use of 
Pyro, the probe combines therapeutic (photodynamic 
therapy) and imaging functions: Pyro is a nontoxic light-
sensitive molecule capable of becoming toxic when 
exposed to light, producing singlet oxygen that disrupts 
the mitochondrial membrane [133-134], inducing in 
turn apoptosis (therapeutic function). This determines 
activation of caspase 3, able to cleave the probe and 
simultaneously to separate the fluorochrome from the 
quencher allowing the fluorescent signal emission and 
the identification of apoptotic cells (imaging function). 
To study in vivo the activity of this probe, mice were 
implanted with liver hepatocellular carcinoma cells and 
after 20 days, mice were injected with PPB [135]. Then 
tumors were illuminated with a laser scan at 670nm (at 
a light dose of 90 J/cm2 per tumor) 3 hours after probe 
administration. The light is able to activate Pyro, and to 
determine the induction of the complete cascade including 
caspase 3 activation and fluorescent signal emission in 
the area of PPB accumulation and PDT treatment. Ex 
vivo analysis showed that this area was highly apoptotic, 
validating the specificity and efficacy of this probe for 
both therapeutic and imaging strategies. 
tUMOr cELL bIOMArKErs
Many other tumor cell targets are used to 
characterize specific neoplasms, providing information 
about cellular features associated with a specific histotype 
and correlated with tumor responsiveness to treatments, 
its aggressiveness and a prognostic indication. With the 
continuous development of in vivo imaging procedures, 
an increasing number of tumor cell biomarker can now 
be non-invasively studied by using adequately labeled 
specific probes. 
The non-invasive assessment of tumor biomarker 
can be of great importance in several steps, from diagnosis 
and staging, to biological characterization of the tumor, 
evaluation of the response to treatment and evaluation of 
residual disease, thus aiding in the prediction of clinical 
outcome and limiting the need for biological samples and 
invasive procedures (such as biopsies).
Non-invasive tumor cell biomarkers can include 
membrane or intracellular receptors for hormones and 
growth factors, adhesion molecules, enzymes and fetal or 
embryonic proteins.
Oncofetal antigens
Some cancer types usually overexpress and secrete 
oncofetal antigens, such as carcinoembryonic antigen 
(CEA) or alpha-fetoprotein: these proteins participate in 
embryogenesis, and their production quickly declines after 
birth. However, high CEA levels or titers of antibodies 
to carcinoembryonic antigen (CEA) are significantly 
detectable in the majority of patients with colon, pancreatic 
and breast cancers. On the contrary, only approximately 
5% of normal individuals have detectable CEA reactive 
antibody titers. 
Regarding CEA expression [136], specific probes 
were developed to detect in vivo this oncofetal protein, by 
labeling specific monoclonal antibodies with Cy5.5 [137], 
Alexafluor488 [138], fluorescent cyanine DY-676 [139], 
QD820 [140], or bioluminescent proteins such as Renilla 
Luciferase [141] and Gaussia Luciferase [142]. Even if 
Renilla and Gaussia Luciferases are not fluorescent probes, 
this is an alternative strategy that can be used to target 
CEA by Optical imaging using Bioluminescence. Renilla 
Luciferase labeled probe (called Db-18-Rluc8) is formed 
by three components: a T84.66 diabody for targeting CEA 
positive cells, a Rluc8 enzyme (an isoform of Renilla 
Luciferase) for oxidation of coelenterazine substrate 
(necessary for light production), and a linker peptide of 18 
amino acids to connect the two subunits. In small living 
animals, Db-18-Rluc8 localized in CEA-positive tumors 
and after injection of coelenterazine, a bioluminescent 
signal can be observed in neoplastic lesions thanks to the 
specific binding of the probe to tumor cells. 
Alternatively, the targeting of alpha-fetoprotein 
(AFP) was carried out through monoclonal antibodies 
against AFP conjugated with Quantum Dots, AFP-QD590 
[143], in order to study the accumulation and retention of 
AFP-QD at the site of xenografted hepatocellular cancer 
tumors, even if, to date, this probe was used only in ex 
vivo fluorescence imaging procedures. 
PsA
Prostate Specific Antigen (PSA) is the most used 
serum biomarker for prostate cancer screening and 
monitoring. However, its expression is not fully specific 
for oncological conditions, since it is present at high 
levels also in benign prostatic hyperplasia or in case of 
prostatitis. In normal tissues or in benign conditions, high 
concentrations of active PSA are stored in the prostatic 
collecting ducts [144]; in this setting only a small 
amount of enzyme can leak out, but it forms a complex 
with its inhibitor, the alpha-1 anti-chymotrypsin (ACT), 
generating an inactive PSA that can anyway be detected 
in serum samples by classical procedures. In cancer, this 
architecture is disrupted, and increased amount of PSA 
is accumulated into the tissue interstitium and is free to 
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leak out in the serum where it is inactivated and detected. 
The higher level of PSA in the interstitium is related to an 
increased tumor growth rate, and can assume a causal role 
in prostate cancer progression [145].
Enzymatically active PSA is detectable only in 
prostatic tumor tissues, and can be considered a more 
specific target for the differential diagnosis of tumors 
from other pathologies. In this scenario, a specific probe 
for the active form of PSA has been developed and it is 
commercially available (Perkin Elmer): PSA 750 FAST 
[146] Fluorescent Imaging Agent. This is an optically 
silent probe in which the fluorescent signal appears only 
after the occurrence of an enzymatic cleavage by active 
PSA. It has been injected in mice bearing subcutaneous 
PSA positive or PSA negative tumors, showing a specific 
probe accumulation and fluorescence activation in PSA 
positive lesions, as validated in ex vivo sections. In fact, 
tumor regions that show extensive perfusion and vascular 
leakage do not show activation of PSA750 probe, because 
the combination with plasma components induces the 
formation of complex of PSA with ACT, resulting in 
ablation of enzyme activity, validating the specificity of 
this probe for the active form of PSA. PSA750 is a unique 
and powerful tool for preclinical prostate cancer research, 
and its future potential translation into the clinical setting 
could be of great benefit for transrectal or laparascopic 
prostatic imaging.
In vivo imaging of PSA has been based also on the 
use of PSA-specific antibodies labeled with ICG [147] 
or QDs [148-149] or PSA-specific small molecules 
used to bind PSA in vivo thanks to their more tractable 
pharmacokinetics and the more rapid washout from non-
target sites, respect to antibodies. These molecules were 
labeled with IRD800CW, IRD800RS, Cy5.5, Cy7, or a 
derivative of indocyanine green (ICG) [150] to assess their 
accumulation by fluorescence small animal imaging.
EGF/EGFr
Epidermal growth factor (EGF) is a 53-amino-
acid membrane protein able to stimulate the growth 
of epidermal and epithelial cells, and involved in 
cell proliferation, survival, adhesion, migration, and 
differentiation [151]. The EGF receptor family consists of 
four transmembrane receptors, including EGFR (HER1/
erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3), and HER4 
(erbB-4) [152]. In oncology EGFR and HER-2 receptors 
have become very important as potential targets of 
biological specific drugs (Figure 5).
EGFR [151] (HER1) is located on cell surface and 
it is activated by different ligands, including epidermal 
growth factor and transforming growth factor α (TGFα). 
Upon activation EGFR becomes active and pairs with 
another member of its family, such as HER2, to create 
an activated heterodimer. The dimerization stimulates the 
activity of protein-tyrosine kinase. Mutations that lead to 
EGFR overexpression or constitutive activation have been 
associated with a number of cancers (e.g. it is up-regulated 
in 60-80% of colorectal cancer [153]), determining 
uncontrolled cell division and tumor proliferation, and 
they are correlated with poor prognosis. 
Different fluorescent probes for EGFR targeting 
have been developed, and they are principally based on 
the use of anti EGFR antibodies labeled with different 
fluorophores. Cetuximab (or Erbitux, a monoclonal 
antibody already used in cancer therapy) has been labeled 
with Cy5.5 [154-156], QD840 [140] or Bodipy-FL [157] 
(a fluorophore that emits at 513 nm). Cy5.5-Cetuximab 
[156] has been injected in mice bearing MCF-7 and MDA-
MB-231 breast cancers, and the tumor localization was 
monitored by fluorescence imaging. Images showed high 
probe accumulation at tumor site, while the administration 
of an excess of unlabeled Cetuximab showed a reduction 
on tumor contrast due to the competition with the labeled 
antibody for the specific target, even if a low background 
signal remained detectable. 
However, the pharmacokinetics of intact mAbs 
showed high liver uptake and slow blood elimination 
[158] (as demonstrated with radiolabeled antibodies), 
confirming that whole Abs are generally not ideal for 
imaging procedures. 
In this regard, a novel class of recombinant affinity 
ligands (Affibody molecules) for EGFR was constructed 
on the basis of a 58-amino-acid Z-domain residue deriving 
from the IgG-binding domain of staphylococcal protein 
A [159], and showing binding affinity to EGFR with 
Kd values of 25-50 nM. These affibodies were labeled 
with Cy5.5 [160-161], AlexaFluor680 [162] or IRD800 
dye[161]. Affibodies labeled with IRD800, called Eaff800 
[161], have been injected in a mouse model of human 
skin carcinoma, showing probe accumulation in tumor, 
kidneys and liver. The tumor signal was detected 1 hour 
post injection, and it increased after 1 day; subsequently, it 
decreased over time. The disappearing of signal was faster 
in non-tumor tissues, producing an increase in tumor to 
background ratio with a peak at 24 hours. In addition to the 
affibodies, single chain antibody fragments, consisting of 
the heavy and light variable chains of an antibody linked 
with a flexible peptide and characterized by a molecular 
weight five times smaller compared to native mAbs, but 
maintaining the same affinity [163-164], were also labeled 
with QD580 [165]. 
One of the advantages of fluorescence imaging is the 
possibility to image multiple specific targets at the same 
time, exploiting different probes labeled with distinct 
fluorophores. Several examples have been described: lung 
carcinoma bearing mice were co-injected with QD800-
RGD, QD820-antiCEA and QD840-antiEGFR [140] and 
MultiSpectral Fluorescence Imaging (MSFI) allowed to 
differentially resolve the information given by the three 
probes. A fluorescent signal was observed for all the 
probes in primary and in metastatic lesions, as well as in 
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lymphatic basin, as expected, since lung cancer can spread 
locally near the tumor or in the regional lymph nodes. 
In primary lesions, QD-antiCEA signal was lower than 
QD-RGD and QD-EGFR, correlating with their different 
expression in the lung tumor in which CEA is less 
expressed than the other two targets (αvβ3 integrins and 
EGFR). These results have demonstrated that these QD 
bio-conjugates may be used as probes for the simultaneous 
detection of multiple tumor markers in vivo.
Since antibodies are approximately 25-fold larger 
than EGFR ligands, they may not be easily transported 
within solid tumors, and in a different imaging strategy 
EGF was labeled with Cy5.5 [166] and IRD800 [167-
168], available from LI-COR Biotechnology - GmbH, 
Bad Homburg, Germany, to study EGFR density on tumor 
cells. The probe was tested in a breast cancer model, 
showing probe accumulation in EGFR positive tumors. 
Pre-treatment with Cetuximab prevented the labeled-EGF 
probe binding in the EGFR positive tumors, validating the 
specificity of the signal.
Erbb2
The human epidermal growth factor receptor 2 
(erbB2, HER2, or neu) [169] is an oncogene involved in 
the proliferation, migration, and invasion of cancer cells; 
for example it has been found to be amplified in 18-20% 
of breast cancers [170]. HER-2 positive breast cancers 
showed a worse prognosis compared to negative tumors, 
but the availability of targeted therapies constituted 
by monoclonal antibodies directed against HER-2 
significantly improved the clinical outcome. In this setting, 
the detection of this biomarker on tumor cells is critical for 
the identification of the best treatment option. 
In this context, trastuzumab (a humanized 
monoclonal IgG1 antibody, already approved for clinical 
use for anti-cancer therapies in both Europe and North 
America) was labeled with different fluorophores (Cy5.5 
[171], AF750 [172-173], AF680 [174-175], RhodamineG 
[176-177], ICG [178] or QD800 [179]). Nowadays it is 
also commercially available as HER2sense, labeled with a 
red fluorophore emitting at 661 nm (Perkin Elmer [180]), 
allowing to in vivo study HER-2 expression mainly in 
mammary tumors. Activatable probes, constituted by 
Cy5.5 or Alexa680 labeled trastuzumab [175] bound to 
a quencher, have been injected in 3T3 sarcoma bearing 
mice. After binding to HER-2, the antibody was gradually 
internalized within HER-2 positive cells, and addressed to 
degradation into the lysosomes. Within these organelles, 
the quencher was separated from the fluorophore, and 
light was emitted. In this way, light emission resulted 
to be specific for HER-2 targeting. Both probes allowed 
the visualization of tumors, but Alexa680 labeled probe 
displayed a higher signal to noise ratio respect to the Cy5.5 
labeled one. In fact, Cy5.5 resulted to be internalized also 
in liver, preventing the possibility to specifically target 
HER-2 positive tumors within this organ. Furthermore, 
it showed also a quote of a-specific binding to HER-2 
negative tumors, probably due to its high lipophilicity, 
charge and molecular weight.
In order to ameliorate the unfavorable 
pharmacokinetics of whole antibodies, as described 
before, Affibody molecules for HER2 were also developed 
from one of the IgG-binding domains of staphylococcal 
protein A [181] (Kd values of <50 nM). In particular, 
the synthetic Affibody molecule His6-ZHER2:342-Cys 
(named ZHER2:342) was labeled with DyLight750 
[182] and QD800 [183]. Moreover, it was fused to an 
Albumin Binding Domain (ABD) to further prolong the 
circulation half-life of the probe, and then was labeled 
with AlexaFluor750 [184] and DY-680 [185]. ABD-
AF750-affibody, called ABD-ZHER2:342, was compared 
to AF750-labeled trastuzumab and with monomer or dimer 
affibodies, showing a strong signal in the mouse model 
around the human SKBR-3 breast tumor and in the kidney 
area, detected since 8 hours after injection (earlier respect 
to Trastuzumab, that localizes at tumor site 24 hours 
after injection), with a peak at 24 hours and a decrease 
after 72 hours (longer than monomeric and dimeric 
affibodies, that showed a weak signal only between 6 and 
8 hours); moreover, the tumor to background ratio was 
higher for ABD-ZHER2:342, suggesting that ABD-fused 
ZHER2:342 could be used as a specific probe for a better 
non-invasive characterization of HER-2 expression in vivo 
[184]. Furthermore, the use of ZHER2:342-DyLight750 or 
AF750 labeled probes permitted an early characterization 
of HER2 expression, thanks to their relatively fast 
pharmacokinetics, allowing a precocious assessment of 
HER2 expression in vivo within a shorter observation time 
[182] and reducing the time window required in future 
clinic application.
In addition, HER-2 expression was targeted also by 
liposome labeled with QDs (named QD-IL) [186]. Anti-
HER2 single chain Fv fragments (scFv) and QD800 were 
attached to the end of PEG chains bound to a liposomal 
core. The probe was intravenously injected in MCF-7 
mammary tumors bearing mice and fluorescence imaging 
showed a strong signal at the tumor site (as well as in 
mononuclear phagocytic system organs where liposome 
were cleared). However, the targeted probe failed in 
showing any difference in tumor uptake from the non-
targeted ones, probably for the enhanced permeability 
and retention (EPR) effect typical of tumors [187-188]. 
Imaging data were validated on ex vivo tumor sections, 
which showed extensive accumulation of the probe 
within tumor cells. These findings showed the important 
role played by liposomes in targeting tumors with the 
possibility to use them as drug delivery system with 
high efficiency, even if the targeting should be further 
optimized.
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IGFr1
The type I insulin-like growth factor receptor 
(IGF1R) is a tyrosine kinase receptor involved in cancer 
progression and metastasis formation [189-191] and its 
over-expression and activation has been reported in many 
cancer types, especially in breast cancer. Moreover, its 
expression is correlated with poor prognosis. Similarly 
to HER2, IGF1R expression monitoring is crucial for 
optimization of treatment efficacy. Different monoclonal 
antibodies are already used in phase I, II, and III clinical 
trials, but no data are available about the expression of 
IGF1R in primary tumors before the beginning of the 
treatment. Experiments carried out on xenograft mouse 
models showed down-regulation of the receptor after 
treatment with these antibodies, followed by a decrease 
in tumor growth [192-193]. For this reason, IGF1R down-
regulation could be used as a biodynamic marker of 
antibody delivery and a potential indicator of treatment 
response. 
In order to easily target the expression of IGF1R also 
in the metastasis, the IGF1R-specific antibody, AVE-1642, 
was conjugated to Cd/Te QD705 and with AlexaFluor680 
[194], both with a peak emission at 705 nm, and probes 
were injected in R-/IGF1R cells bearing mice, in 
which IGFR1 is depleted, or in MCF-7 tumors bearing 
mice, whose tumors express high IGF1R level; probe 
accumulation was followed by fluorescence imaging. Mice 
injected with QDs-AVE-1642 showed fluorescent signal in 
liver, spleen, lymph nodes and bone marrow, all organs of 
the reticulo-endothelial system (RES) able to phagocyte 
nanoparticles, and are characterized by highly permeable 
sinusoids, which allow the extravasation of the probe, but 
no signal could be detected in tumors. Ex vivo analysis 
confirmed that no fluorescence could be detected in tumor 
masses, and also down-regulation of IGFR1 was not 
observed. In addition, mice were treated with clodronate, 
in order to deplete macrophages in RES, however no 
signal was detected at tumor level. On the contrary, mice 
injected with AlexaFluor680-labeled antibodies showed 
specific tumor signal from 1 to 4 days post-injection, 
whereupon signal decreased in the following 10 days (and 
no signal was detected in the abdominal area). Ex vivo 
data confirmed the imaging data, demonstrating also a 
down-regulation of the receptor. These findings suggest 
that antibodies labeled with small molecules efficiently 
allow to image IGFR1 expression and its down-regulation. 
sstr2
Finally, Somatostatin Receptor, especially the 
subtype 2 (SSTR2), is another tumor cell marker found 
to be up-regulated in neuroendocrine (but also in some 
non-neuroendocrine, such as breast cancer and lymphoma) 
cancers [195]. Furthermore, it has been also found to be 
up-regulated in proliferative endothelial cells near tumor 
masses. For these reasons, it has been identified as a target 
for anti-cancer therapy. 
In the clinic, the 68Ga-DOTATOC is routinely used 
for the differential diagnosis of neuroendocrine tumors. 
This probe is based on ocreotate, a stabilized analog of 
somatostatin labeled with 68Ga [196].
According to clinical procedures and with the aim 
to target this receptor for optical imaging, octreotate, 
was labeled with indotricarbocyanine [197] (ITCC) or 
with 5-carboxy-fluorescein [198] (emitting at 518 nm it 
was revealed by intravital microscopy imaging). ITCC-
ocreotate was injected in mice bearing subcutaneously 
implanted RIN38 β-cells: fluorescence imaging showed an 
increase of the tumor to normal tissue ratio immediately 
after intravenous injection, and between 3 and 24 hours, 
the signal intensity in the tumor was three fold higher 
than in normal tissues. Other cells normally expressing 
somatostatin receptors were not detected during this 
procedure: for example, neuronal cells of the central 
nervous system did not show any signal, probably because 
the probe is not able to cross the blood/brain barrier, 
whereas neuroendocrine cells escape the visualization 
because they are dispersed within organs.
Since somatostatin receptors are over-expressed 
by the majority of gastric and breast cancers, the use of 
fluorescent labeled probes might help in the intraoperative 
identification of tumor lesions. 
GPcr
The G-Protein Coupled Receptors (GPCRs) form 
a big receptor family involved in the transduction of 
different kind of signals [199-200]. These receptors are 
formed by seven-transmembrane α-helices, and after 
binding with the specific ligand, they expose intracellular 
sites which interact with the G-protein heterotrimer 
containing α, β and γ subunits. This process determines 
the dissociation of bound GDP and the binding of GTP to 
α subunit, resulting in the dissociation of α-GTP and β γ 
subunits, which in turn are capable of activating different 
downstream pathways and effectors. 
These receptors are embroiled in neurotransmission, 
hormone and enzyme release from endocrine and exocrine 
glands, immune response, muscle contraction and other 
physiological conditions. Recently they were found to be 
upregulated during tumorigenesis and linked to cancer 
progression and metastasis, by increasing proliferation 
and vascularization, evasion of immune surveillance, 
and increasing microenvironment invasion and tumor 
cell dissemination. They are also correlated to chronic 
inflammation and tumor establishment. As a consequence, 
targeting of GPCR could provide information about cancer 
detection and therapy. 
Even if there is a broad range of ligand for GPCR, 
only two mitogen acting through this class of receptor, 
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have been labeled with AF680 or Cy5.5 to perform 
oncological imaging: gastrin and endothelin, respectively. 
Gastrin [201] is well established as a growth factor 
for the gastro-intestinal tract and the pancreas, and acts 
through activation of MAP kinase pathway effectors, e.g. 
ERK1/2, JNK, p38-MAPK and STAT3. Its expression has 
been observed in different kinds of cancer, such as colon 
cancers and primary colorectal carcinomas. Moreover, 
it has been found upregulated in other solid tumors with 
endothelial origin: gastric, pancreatic lung and ovarian 
cancer [201]. By autocrine effect on GPCR, gastrin 
realizes its effect, and the over-expression is mainly 
due to the deregulation of different oncogenes affecting 
downstream the gastrin promoter activity.
Gastrin peptide was labeled with AF680 (AF680-
gastrin) [202-203], and imaging was performed to detect 
breast and prostate cancer lesions. AF680-labeled probe 
was intravenously injected in immunodeficient T-47D 
breast cancer bearing mice [202] and fluorescence imaging 
was performed after 15 minutes. Images showed high 
probe localization at the tumor masses. When unlabeled 
gastrin peptide was injected before probe administration, 
only a little signal could be visible, showing the high 
specificity of the probe. In a second set of experiments, 
mice injected with PC3 cells were followed over time 
[203], and in addition to probe localization within primary 
tumor, AF680-gastrin-based probe permitted also the 
detection of micro-metastases on the retroperitoneal wall 
under the kidneys and in the lumbar region near aorta. 
MRI and the ex vivo validation by means of histopathology 
procedures confirmed that they were clusters of tumor foci 
with sizes of approximately 200-400 mm in diameter.
Endothelin 1 (ET-1) [204] acts, in physiological 
conditions, to constrict blood vessels and raise blood 
pressure. Its cognate Endothelin A receptor (ETAR), 
belonging to GPCR class, has been found to be 
upregulated in different kinds of solid tumors, including 
thyroid, ovarian, prostate, colon, breast, bladder and lung 
cancers and it is involved in survival and proliferation of 
cancer cells, in migration, stemness and therapy resistance. 
In fact, ET-1 induces the activation of phospholipase C, 
which in turn influences calcium metabolism and activates 
protein kinase C: this enzyme regulates the proliferation of 
surrounding cells through activation of MAPK pathways, 
affects the apoptosis (by altering phosphorylation 
pathways), and promotes neoangiogenesis (by increasing 
growth factor transcription, e.g. vascular endothelial 
growth factor). Starting from these considerations, the 
in vivo visualization of ET receptor expression would 
be interesting for the staging and evaluation of therapy 
response. 
ET-1 peptide was labeled with Cy5.5 (Cy5.5-
Endothelin) [205] and a biodistribution study was 
performed in healthy mice showing probe uptake in 
the lungs, followed by kidneys, liver, heart, spleen and 
muscles. The lowest signal was detected in the brain. 
After 24-48 hours, the signal strongly decreased in 
all organs except lungs, which showed only a modest 
reduction. Then, the probe was tested in an orthotopic 
model of papillary thyroid cancer (K1 cell line) [206], that 
expresses high level of ETAR, and showed high fluorescent 
signal localization at tumor level up to 48 hours after 
tracer administration. The specificity of probe targeting 
was demonstrated by using PD156707 as blocking 
agent: imaging showed a reduction in probe uptake, if 
injected after receptor blocker. Moreover, the probe was 
tested in subcutaneous xenograft models obtained using 
two mammary cell lines (BT-20 and MDA-MB-231), a 
fibrosarcoma cell line (HT-108) and the already used K1 
cell line (thyroid cancer). In vitro ETAR was found to be 
expressed in HT-108 and MDA-MB-231 cells (beyond 
K1 cell line), whereas no expression was found in BT-
20 tumors, which express ET
B
R. K1 and HT-108-derived 
tumors showed high probe uptake in the whole imaging 
period, whereas BT-20 and MDA-MB-231 did not show 
a specific uptake, and the fluorescent signal was similar 
to muscles. 
These data support the implementation and the 
use of intraoperative or endoscopic imaging devices, 
particularly when clinical practice is easy to image: for 
example, its use in the fluorescence-guided thyroidectomy, 
similarly to the procedure used in neurosurgery.
trANsLAtION INtO cLINIc
Recent improvements in technology and scientific 
knowledge have introduced the use of Near-Infrared 
Fluorescence Imaging into clinics, and in the last decades, 
fluorescence has been used to guide surgeons during 
oncologic interventions. Conventionally, the navigation 
was done using X-ray fluoroscopy or ultrasounds. 
However, even if these techniques provide anatomical 
information, they do not provide findings about a specific 
molecular process or target. Moreover, fluoroscopy 
exposes patient and medical staff to ionizing radiation, 
while ultrasounds require a direct contact with the tissue, 
with obvious problems in an intraoperative setting. 
Fluorescence Imaging offers the possibility to overcome 
these limits, providing good sensitivity and specificity. 
Among all available fluorophores, ICG is the only 
near-infra red dye, emitting at 820 nm, approved by FDA 
(Food and Drug Administration) and EMA (European 
Medicines Agency) for use in humans. The current 
indications are the determination of cardiac output, hepatic 
function, liver blood flow and ophthalmic angiography. 
Moreover, it has been used for lymphatic system imaging, 
and its use was tested also for nodal staging in cancer and 
breast lesion characterization (discrimination between 
malignant and benign lesions) [207]. All these last 
applications are important in the oncology field, and will 
be discussed below.
Lymphatic System is difficult to visualize, because it 
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cannot be cannulated, but alterations in lymphatic flux and 
function are sometimes associated to cancer metastasis 
and to lymphedema following nodal staging surgery. 
ICG allowed to visualize the direction of lymphatic flux, 
following intradermal administration, to the draining 
lymph node: in a healthy person, the flux is linear, 
and velocity or pump frequency can also be recorded. 
Conversely, lymphatic system visualization in a patient 
affected by lymphedema after breast cancer treatment, 
showed altered functions, including lymphatic reflux, 
reduced pumping activity, tortuous and leaky vasculature, 
and incomplete ICG uptake [207-208]. 
Another potential application for ICG is the 
evaluation of sentinel lymph node (SLN) for nodal staging 
of cancer, especially for breast and melanoma cancer. 
In general, the identification of SLN is carried out with 
99mTc, but the use of both mg-doses and micro-doses of 
ICG allowed to estimate the SLN at 5 cm of depth during 
breast surgery, with good concordance with scintigraphic 
imaging [207,209-210]. The identification of SLN is being 
evaluated also in other tumors, such as prostate, gastric, 
lung, and skin cancers [211-214].
The third application, which has been recently 
tested, is the use of ICG to characterize primary breast 
cancer lesions: in fact, the clearance of ICG from tissues 
can be influenced by the presence of leaked vessels 
that is a common feature of tumors, and could help in 
the discrimination of malignant lesion from benign 
disease. Human breast imaging has been performed 
by using tomographic techniques, that are based on the 
measurements of NIR absorption and fluorescence before 
and after administration of ICG and on a mathematical 
model of light propagation and fluorescence generation in 
tissues, in order to generate a 3D map of optical properties 
that delineates and characterizes breast lesions. 
There are very few works about this application: 
in two pilot studies a clear absorption increase was 
observed in the malignant tumors due to accumulation of 
injected-ICG [215-216] and in another study [217], late 
contrast of ICG, compared to early contrast, was able to 
better differentiate malignant and benign lesions, with 
good agreement with conventional mammography or 
ultrasonography [207]. 
Summarizing, ICG fluorescence for lymphatic 
vasculature diagnosis and assessment of its function is safe 
and minimally invasive, and can be performed repeatedly. 
Moreover, reported examples highlighted the possibility to 
use a micro-dose of ICG dye to perform imaging, reaching 
the micro-dose of radiolabeled probe, that is generally 
defined as “less than 1/100th of the dose calculated to 
yield a pharmacological effect of the test substance to a 
maximum dose of < 100 micrograms” [218]. In addition, 
the acquisition is very fast, lasting milliseconds, and ICG 
allows to visualize even the contractility of lymph vessels, 
a finding difficult to detect with the other techniques. 
ICG has been also used in some clinical trials 
dealing with other cancer types. For example, it has been 
tested to evaluate the best perfused area for the surgeon 
to perform transection and anastomosis during colorectal 
surgery (ClinicalTrials.gov Identifier: NCT02598414): 
this is the principal cause of morbidity and mortality in 
this kind of surgery. The imaging has been performed 
by intravenous injection of 2.5 mg/ml of ICG, and this 
procedure has been repeated twice during surgery, before 
and after the anastomosis. The microvascularization at 
the anastomosis site has been assessed using a robotic 
fluorescence imaging device (FireFly™). In addition, 
ICG has also been proposed for the evaluation of the 
extent of kidney tumors, with the aim to scheme the 
surgery (ClinicalTrials.gov Identifier: NCT01281488). 
The primary objective has been the determination of 
the optimal dose of ICG for the visualization of renal 
carcinoma, and the secondary objectives were focused 
on report of peri-operative outcomes, such as resected 
margins, perfusion and renal function, operation time and 
correlation with intraoperative ultrasound imaging and 
preoperative imaging. 
As well as ICG, other fluorescent dyes or tracers are 
used in clinical trials, even if they are still ongoing and 
no results are yet available; some examples are reported 
below. 
In a glioma clinical trial (ClinicalTrials.gov 
Identifier: NCT02473380), fluorescence spectroscopy 
has been used to visualize glioma mass during surgery 
by using 5 amino-levulinic hydrochloride (GLIOLAN) 
as a-specific contrast agent. It is an un-fluorescent oral 
preparation that is absorbed by cells, especially by glioma 
cells or cancer cells, where it is principally converted 
in Protoporfirin IX (PPIX). When excited by a blue 
light, PPIX emits red fluorescence, while healthy tissues 
remain blue. This differential diagnosis allows surgeons 
to perform a more accurate resection of cancer lesions, 
without affecting normal brain portions.
Beside the use of a-specific contrast agents, some 
clinical trials entail the use of targeted fluorescent agents, 
with the aim to visualize a specific molecule expressed 
by tumor cells. An example of these clinical trials is the 
use of a near infra-red labeled folate analog, the OTL38, 
in order to detect renal cancer carcinoma at the resection 
margins in partial nephrectomy and lymph node or other 
sites of metastasis in radical surgery (ClinicalTrials.gov 
Identifier: NCT02645409) to better and faster evaluate the 
outcome of operation.
The last example is the use of Bevacizumab, which 
has been labeled with IRDye800CW and has been used 
during endoscopy in patients with hereditary colon 
cancer syndromes like Familial Adenomatous Polyposis 
(ClinicalTrials.gov Identifier: NCT02113202), that 
showed overexpression of VEGF, the target molecules of 
the monoclonal antibody Bevacizumab. The study is based 
on the idea that bevacizumab-IRDye800CW accumulates 
in VEGF expressing adenomas after its administration, 
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enabling tumor visualization using a newly developed 
near-infrared (NIR) fluorescence endoscopy platform 
(NL43407.042.13). 
The same tracer has also been used in another trial 
for the visualization of rectal cancer, in order to detect the 
presence of the drug target, in this case VEGF, to identify 
those patients who could benefit from a specific targeted 
treatment (ClinicalTrials.gov Identifier: NCT01972373). 
All these examples seem to support the importance 
of fluorescence imaging during surgery or endoscopic 
imaging, with the aim to obtain fast and safe information 
about cancer mass and margins, its characterization and to 
facilitate complete surgical removal. 
LAbELING OF NEWLY DIscOVErED 
cELLULAr tArGEts
Different processes and molecules can be easily 
visualized by using fluorescent probes, but in the future 
the need will arise to detect newly discovered cellular 
targets. An example of this process has been described 
in a very recent article of Salanti A. et al [219]. In this 
work, the authors have explored the anchor protein 
VAR2CSA, involved in the binding of Malaria-infected 
erythrocytes to placental syncytioblasts, in order to 
avoid the splenic clearance of infected cells. VAR2CSA 
binds a specific type of glycosaminoglycan (GAG), the 
chondroitin sulfate GAG, called CSA, that was found to be 
expressed in 95% of tumors generated by hematopoietic, 
epithelial and mesenchymal cells. The authors labeled 
the recombinant VAR2CSA protein with two different 
fluorophores, the Alexa488 and Alexa750 to perform 
in vitro and in vivo imaging, respectively. Data showed 
rapid in vitro internalization within 30 minutes in a colon 
cancer cell line (Colo205), and specific in vivo uptake, 
after intravenous administration, in xenograft mice bearing 
prostate (PC3 cell line) or melanoma (B16 cell line) cancer 
lesions. These data supported the possibility to use new 
targets in addition to the already used ones to visualize 
tumors. Moreover, since VAR2CSA is rapidly internalized 
after binding with CSA, this mechanism could be explored 
as a targeted strategy for the specific drug delivery to 
tumor.
In this paragraph we will explore the different 
possibilities among newly discovered cellular targets; 
moreover, an elucidation of the possibilities to conjugate 
fluorophores and targets and the criteria for the right 
choice of labeling molecules will be provided. 
Among the newly discovered potential targets 
there are many different molecules ranging from 
polysaccharides, proteins, amino acids (where 
substantially there are no currently available fluorescent 
probes), peptides, as well as larger particles, such as 
nanoparticles and vesicles. Moreover, inasmuch as 
miRNAs have lately acquired a great importance in cancer 
development, establishment and progression, they could 
include new targets to study for the development of new 
probes for cancer detection and visualization.
A fluorescent molecule, to be considered a suitable 
label for in vivo imaging, needs to satisfy different 
requirements:
- it should be excited without contemporaneous 
excitation of surrounding tissues, and the emission should 
be detectable with conventional devices;
- it should have high brightness, molar absorption 
(calculated as absorbance divided by the absorption in 
the path through tissues) and quantum yield (calculated 
as number of emitted photons occurring per number of 
absorbed photons); 
- it should have chemical groups capable of binding 
different kinds of molecules; 
- it should be soluble in different aqueous fluids, 
stable in the most common conditions and non-toxic.
Biomolecules can be labelled by fluorescence, as 
shown in the examples reported in the paragraphs above, 
using organic molecules, semiconductor nanocrystals, and 
fluorescent proteins. 
The field of organic fluorescent molecules is bigger, 
and is characterized by availability of dyes with different 
wavelengths, ranging between near-ultraviolet to near 
infra-red. However, despite the broad range of dyes, only 
a small part of the spectrum can be used to perform in vivo 
imaging. In fact, in the body tissues are present molecules 
that are natural chromophores, which strongly affect the 
incident or emitted flux of exogenous fluorescent probes 
by absorbing photons. This phenomenon decreases by 
increasing the wavelength of radiation, and is dependent 
upon the tissue features and its physical state [220]. For 
examples, tissues that contain high level of hemoglobin 
strongly absorb photons in the range of blue-green 
emission (e.g. 400-470 nm), but this phenomenon becomes 
negligible for wavelengths higher than ~600 nm. In fact, 
once passed this threshold, the tissues become quite more 
transparent to photons, and red and near-infra red emitting 
fluorescent dyes result the best choice for in vivo imaging 
FLI strategies.
Among fluorescent molecules emitting at >500 nm, 
that is the minimum wavelength to avoid absorption by 
hemoglobin, Rhodamines, AlexaFluor and Cyanine dyes 
are the most commonly used fluorophores for molecule 
labeling. 
Rhodamine [221] is the oldest synthetic class of dyes 
used to label molecules. They generally are characterized 
by high molar absorptivity in the visible region and high 
brightness. Modern rhodamines are linked either non-
covalently or covalently to target molecules, and the 
most exploited fluorophores are Rhodamine G [222] and 
Rhodamine 800 [223]. The former has an excitation peak 
at 526 nm, and an emission at 548 nm, whereas the latter 
is characterized by a double peak of excitation at 623 and 
682, a double peak of emission at 700 and 774 nm, good 
photostability, a very low anisotropy and an acceptable 
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fluorescence quantum yield. 
AlexaFluor [224] is a family of dyes owned by 
Molecular Probe, Inc. They are synthesized by sulfonation 
of already existing molecules, such as coumarin, 
rhodamine, fluorescein and cyanine dyes, making them 
negatively charged and hydrophilic. In general, the Alexa-
Fluor derivative dyes are characterized by higher stability, 
more brightness and less sensitivity to pH compared to 
the organic dyes with comparable fluorescent spectra. 
Their emission spectra range between 442 and 805 nm, 
with a great availability of probes in the red and near-infra 
red window. However, their use is limited due to the costs. 
Cyanines [221] are fluorescent compounds 
having two aromatic or heterocyclic rings linked by a 
polymethine chain with conjugated carbon-carbon double 
bonds. Currently they are the main source of labeling 
fluorophores, showing an excitation and emission 
bands ranging between 600 and 900 nm. Moreover, 
they show linear and easy synthesis, possibility to tune 
their wavelengths, high near infra-red absorption and 
emission, and large molar absorptivity. They show some 
disadvantages as well: short fluorescence lifetimes, low 
fluorescent quantum yields and sometimes they undergo 
aggregation in aqueous solutions, determining low final 
fluorescence intensities. Some of the drawbacks could 
be sort out. For example, by using macromolecules or 
organic solvents, the solubility could be improved, or 
the introduction of alkyl sulfonate groups could allow to 
ameliorate water solubility, quantum yield and stability. 
Moreover, it is possible to insert additional functional 
groups to facilitate their covalent binding to target. 
Examples of compounds belonging to this fluorescent class 
are Cy5 and ICG. Cy5 is excited at 650 nm, and emits at 
670 nm. Thanks to its fluorescent spectra in near-infra red 
region and its high extinction coefficient it has become 
particularly attractive for probe labeling. In addition, its 
derivative Cy5.5 shows a more shifted spectrum in NIR, 
being excited at 678 nm and emitting at 694 nm. ICG 
[225] is a tricarbocyanine dye with a molecular weight of 
751.4 Da, able to emit at 800 nm and longer, depending 
on its chemical environment and physical condition. Even 
if it tends to aggregate and shows a very low fluorescence 
efficiency in aqueous solution, the use of solvent and the 
binding to proteins or molecules reduce these problems, 
and its approval by FDA for clinical use [207,226], makes 
it a useful tool during intraoperative decision making (as 
already explained in the previous paragraph). 
Fluorophores able to emit at <500 nm could be 
used in in vitro studies, as well as in restricted in vivo 
applications where photon attenuation due to absorption 
by the tissues is not a limiting factor, e.g. endoscopic 
procedures [227]. 
The second possibility to label molecules is using 
semiconductor nanocrystals [228], such as Quantum 
Dots (QD). They are small light-emitting particles on the 
nanometer scale, formed by a core of CdSe, generally 
overcoated with ZnS, but also with CdS, ZnSe, CdTe 
and PbSe. Their optical proprieties are determined by 
the materials used for the coating and the emission 
color is dependent upon their size. For example, a small 
nanocrystal of 2-nm core emits green fluorescence 
-maximum 550 nm, 15% quantum yield- whereas a 
larger one, of about 4-nm core, emits red fluorescence 
-maximum 630 nm, 6% quantum yield-, reaching until 
2 um of wavelength in the far-red. Moreover, they are 
characterized by high quantum yield and molar extinction 
coefficients (10-100 fold higher than organic dyes), 
broad spanning of emission, high resistance to photo-
bleaching and to photo- and chemical-degradation [229]. 
In addition, a great advantage of QDs is that their surface 
could be functionalized with the aim to target biological 
molecules, either through electrostatic and hydrogen-
bonding interactions or through a specific ligand-receptor 
interaction. The cytotoxicity of QDs is comparable with 
those of more commonly used fluorophores [230], and 
QDs have other advantages compared to organic dyes 
[231]: they are characterized by narrow emission band, 
the excitation and emission spectral position are tunable 
in relation to the size (quantum size effect), the molar 
absorption is higher, the quantum yield is good for both 
visible and near-infra red wavelengths (in contrast, organic 
dyes have fluorescence quantum yields that are high in 
the visible light range but are at best moderate in the 
NIR wavelength range) and the lifespan of fluorescence 
is longer (that last feature can sometimes represent a 
disadvantage, because it could make harder to quantify 
the signal in relation to time). In addition, QDs allow to 
perform two-photon imaging and multiplexing.
Even considering all these advantages, could these 
agents definitively replace fluorescent dyes? The answer 
is no, even if they can become complementary, especially 
in the field of in vivo imaging. Fluorescent dyes are an 
easy, safe and quite inexpensive strategy to label probes, 
they are commercially available, there are well-established 
protocols for their use and their proprieties are largely 
studied. Conversely, QD use is limited because their 
commercial availability is restricted, sometimes the signal 
quantification is difficult and there is the need of approved 
protocols for their functionalization. 
The last option for the labeling of molecules is 
the use of recombinant fluorescent proteins [232]. These 
proteins represent a useful tool to visualize processes 
or molecules in vivo; in fact they can be designed to 
respond to a much greater variety of biological events 
and signals. However, they are generally used through 
their introduction into cell genome, and not as molecule 
labels, and no examples are reported for their use as 
labels in oncological imaging applications. Conversely, 
Luciferases, used to perform Bioluminescence Imaging, 
were sometimes utilized to label probes (such as in the 
examples reported for CEA antigens in paragraph 3.1). 
This strategy is not the best choice, because enzymes are 
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bigger than other dyes and, in addition, Luciferase requires 
the administration of a substrate to be metabolized to 
generate light.
Once identified the right fluorescent dye, and 
performed the appropriate chemical preparation, the 
labeled probe needs to be tested for specificity, in order to 
establish if the molecule modifications have affected the 
behavior of the probe, and for sensitivity, to evaluate if 
the fluorophore provides a sufficiently high signal to noise 
ratio.
Although the number of available fluorescent dyes 
is high, there are still limitations, both in the physico-
chemical characteristics and in fluorophore wavelength 
availability, especially in the near infra-red region, that is 
the best light windows to perform in vivo imaging. Thus, 
there is a strong need for new dyes with improved water 
solubility, higher quantum yield, wavelength emission 
>600÷700 nm and possibility to link them to target 
molecules. 
bOX 1. PrObEs FOr VEssELs 
VIsUALIzAtION
An alternative to integrin for targeting angiogenesis 
consists in probes allowing the visualization of whole 
vascular network. 
A “smart probe” called AngioSense has been 
developed (Perkin Elmer). It is a NIR fluorescent 
macromolecule capable of visualizing the vasculature and 
the blood vessel density [233-235], remaining localized 
over time in the vasculature and permitting to indirectly 
assess blood vessel density, vascular leakage and 
angiogenesis, allowing the study of treatment effects on 
vasculature as well. Moreover, two different fluorophores 
with different wavelengths (680 and 750 nm) are available 
to label this probe, making it possible to simultaneously 
follow two different probes, thus studying two different 
processes, such as angiogenesis and proliferation or 
hypoxia, in the same animal. 
In the same way, AngioSPARK, a new family of 
highly fluorescent near infrared nano-particles specifically 
designed for in vivo imaging are already commercially 
available (Perkin Elmer). AngioSPARKs contain an iron 
oxide core coated with pegylated fluorescent molecules 
to specifically produce functionalized biocompatible 
nanoparticles that remain localized in the vasculature for a 
quite long period of time, allowing to perform imaging of 
blood vessels and angiogenesis and of vascular leakage at 
the site of inflammation and in cancer by optical imaging 
and by MRI. 
In addition, a newly proposed approach entails the 
use of the tomato protein (L. esculentum) lectin, to obtain 
a new probe named TLectinSense680TM, useful for 
vascular labeling. This protein has high binding affinity 
for glycoprotein N-acetylglucosamines on the surface 
of vascular endothelial cells, allowing the targeting of 
vasculature and enabling blood vessels and angiogenesis 
imaging by further conjugation with a near infra-red 
emitting fluorophore. In a recent work, it has been used 
for improving the efficacy, early detection and monitoring 
of the effect of anti-angiogenic therapies [237].
Lastly, LI-COR company has developed a new probe 
(called IRDye 800CW PEG Contrast Agent) for Enhanced 
Permeability Retention (EPR) effect, that is of particular 
importance in cancer: the endothelium of vessels present 
in the tumor microenvironment is often discontinuous, and 
molecules are able to diffuse into the surrounding tumor 
tissue. In addition to EPR effect, the lymphatic drainage 
is reduced. As a consequence, larger molecules tend to 
accumulate. IRDye 800CW PEG Contrast Agent is a non-
specific imaging agent for the visualization of EPR in 
tumor, for example in oral cancer [238].
cONcLUsIONs
To date, clinical trials have a crucial role in 
determining whether fluorescent imaging probes could be 
effective and safe, but human in vivo studies are limited, 
being mainly based on the use of nuclear imaging and 
magnetic resonance techniques. In this scenario murine 
models can help in developing new fluorescent probes and 
in understanding their potential.
In the meantime, different kinds of probes have 
already been developed for optical imaging of tumor 
metabolism, proliferation, hypoxia, angiogenesis, 
invasiveness, inflammation and apoptosis, as well as for 
the early identification of tumor establishment and its 
characterization in relation to the response to treatments. 
Pre-clinical studies demonstrated the versatility of optical 
imaging strategies in the non-invasive assessment of 
these specific biomarkers, emphasizing the importance of 
their early detection to set up more powerful therapeutic 
strategies.
Clinical translation of these procedures has two 
main limitations: the first involves the use of fluorescence 
imaging in humans and the physical limitations that 
could be overcome by introducing new fluorophores or 
endoscopic or intra-operatory imaging procedures; on the 
other hand several of the probes described in this review 
have not yet been approved for human studies although 
significant steps have been made to study their sensitivity 
and specificity and the absence of toxic or adverse effects. 
Once these agents will be approved for clinical practice, 
optical imaging will have the potential to improve 
complete surgical resection of tumors by real-time image-
guided surgery, as well as, to in vivo characterize the 
tumor without the need of potentially harmful procedures 
using ionizing radiations. 
Fluorescent probes can also be efficiently used in 
animal models of human cancers for the validation of 
new targets and new targeted imaging strategies. The use 
of probes already approved for clinical applications in 
Oncotarget48778www.impactjournals.com/oncotarget
nuclear or radiological imaging could help in increasing 
the translational potential of the pre-clinical results 
regarding tumor characterization and stratification for 
the improvement of response to treatment. At the same 
time the identification of fluorophores applicable in the 
clinical setting and the development of new devices 
for fluorescence imaging in humans could speed up the 
clinical translation of these new probes.
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